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ANALYSIS OF THE ROLE OF OUTER SURFACE PROTEIN C (OSPC) IN BORRELIA
BURGDORFERI PATHOGENESIS
By DeLacy V. L. Rhodes, PhD
A Dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2011
Major Director: Dr. Richard T. Marconi
Professor, Department of Microbiology and Immunology

Lyme disease is an emerging infection that is caused by the Borrelia burgdorferi
sensu lato complex. These bacteria exist in nature through an enzootic life cycle
involving Ixodes ticks and various reservoir hosts. One way that this bacterium adapts
to the different hosts in the enzootic cycle is through the expression of outer surface
protein C (OspC). OspC is a surface exposed lipoprotein encoded on circular plasmid
26 that forms homodimers on the bacterial surface and has distinct conserved and
variable portions of sequence. When ospC is deleted, the spirochetes are unable to
cause mammalian infection although the mechanism of this is unknown. Additionally,
OspC is thought to be involved in reservoir host specificity/association and in tissue

dissemination. In order to better understand the functional domains of OspC, the
different conserved and variable portions of this protein were investigated.
Three conserved portions of OspC were investigated: (1) the conserved cysteine
residue at position 130 (C130), (2) the last ten C-terminal amino acids (C10), and (3)
ligand binding domain 1 (LBD1). The C130 residue was mutated and this substitution
disrupted OspC oligomerization in vitro and in vivo. A B. burgdorferi strain lacking the
C10 retained full infectivity and plasminogen binding. The mutation of a single residue
within LBD1 rendered B. burgdorferi noninfectious, indicating the importance of this
domain in infection establishment.
The variable portion of OspC was investigated by: (1) altering the surface charge
of ligand binding domain 2 (LBD2), (2) inserting different OspC types into a constant
genetic background, and (3) creating OspC hybrids. Alteration of the surface charge of
LBD2 by site directed mutagenesis resulted in a lack of persistence in mice. By
inserting an OspC type known to be noninfectious in mice into an infectious strain,
infectivity was abolished. Strains expressing OspC hybrids indicated that multiple
domains of OspC are involved in species specificity.
Together these analyses demonstrated that OspC is as important protein that
plays multiple roles in pathogenesis. The work presented here helps to increase the
understanding of this crucial protein and the strains described can be used to decipher
the full function of OspC.

Chapter 1: Introduction

1.1 Lyme disease
1.1.1 History
Lyme disease, an emerging zoonotic infection, was recognized as a clinical
disease in North America in 1977 (Steere et al., 1977a; Steere et al., 1977b; Steere et
al., 1978). The unusually large occurrence of cases of arthritis in children in Lyme, Old
Lyme, and East Haddam, Connecticut during this time led to a large epidemiological
study to identify the cause of this disease. In 1982, a tick-borne spirochete was
discovered by Willy Burgdorfer, Allen Steere and Jorge Benach. Dr. Burgdorfer was
able to isolate these previously undescribed spirochetes from hard-body Ixodes ticks
from Shelter Island, New York while Drs. Steere and Benach were able to isolate the
spirochetes from patients exhibiting symptoms of Lyme disease, implicating the
spirochetes as the causative agent (Burgdorfer et al., 1982; Steere et al., 1983). The
newly discovered spirochete was able to be cultured in media that had been developed
for other spirochete species and was found to belong to the genus Borrelia. This
spirochete was eventually designated Borrelia burgdorferi (Johnson et al., 1984).
Polymerase chain reaction (PCR) was used retrospectively on preserved tissue
samples and showed that B. burgdorferi was a distinct clinical entity that could be
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detected in samples dating as far back as 1894 (Marshall et al., 1994; Persing et al.,
1990). Similar symptoms of Lyme disease had been noted during the 20 th century in
Europe. Shortly after the discovery of B. burgdorferi in North America these spirochetes
were also recognized as a cause of Lyme disease in Europe followed by the discovery
of the other Lyme spirochete species B.afzelii and B.garinii.
1.1.2 Epidemiology
Lyme disease is the most commonly reported vector-borne disease in North
America and Europe. According to the Centers for Disease Control and Prevention,
approximately 30,000 cases of Lyme disease were reported in 2009, although the
actual number of cases is thought to be much higher due to lack of reporting and correct
diagnosis (Yound, 1998) (Figure 1A). Since the identification of the causative agent of
Lyme disease in 1982, the number of cases has steadily risen each year.

Cases of

Lyme disease in the United States are concentrated to the northeast with the states of
Delaware, Connecticut, New Jersey, Massachusetts, Pennsylvania, and New York
having the highest per capita incidences (McNabb et al., 2007). In addition to the
northeastern states, the midwestern states of Wisconsin and Minnesota also report a
high number of Lyme disease cases (Figure 1B). Lyme disease exhibits a bimodal age
distribution with the peak ages being 5-9 and 55-59 years old. There is no gender
predilection of Lyme disease cases. Cases of this disease usually occur between June
and August when the nymphal ticks feed and people are most often to engage in
outdoor activities (Bacon et al., 2008).
1.1.3 Clinical disease
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Figure 1. Incidence and number of Lyme disease cases in the United States. (A) Lyme
disease case numbers from 1995-2009. Shown are the number of cases reported to
the Centers for Disease Control and Prevention. (B) Lyme disease incidence map.
Each spot on the map corresponds to one reported case. The source of each figure is
given below.
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A

http://www.cdc.gov/lyme/stats/chartstables/casesbyyear.html

B

http://www.cdc.gov/lyme/stats/index.html
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The bacteria that cause Lyme disease are transmitted primarily by the nymphal
stage of infected Ixodes ticks. The ticks must feed on their host for approximately 48
hours in order for the spirochetes to migrate into the host tissue (Piesman, 1993).
Once the spirochetes enter mammalian skin, they disseminate laterally from the site of
the tick bite, resulting in the pathognomonic skin rash, erythema migrans (EM) (Afzelius,
1910). This “bull‟s eye” rash is called so due to a central zone of clearing that occurs in
some patients. The EM commonly occurs at the site of tick bite but in some patients
this rash can occur on other parts of the body or not at all. Other symptoms of early
Lyme disease include fever, headache, arthralgia, regional lymphadenopathy, and
malaise (Nadelman and Wormser, 1995). If left untreated, Lyme disease can present
with late stage sequelae such as arthritic, cardiac, neurological, and/or dermatological
symptoms. These different late stage symptoms can be debilitating and tend to
associate with different species of Lyme Borrelia. Severe dermatological symptoms are
associated with B. afzelii while arthritic conditions occur commonly with B. burgdorferi
infection and neurological complications occur more frequently with B. garinii (Balmelli
and Piffaretti, 1995; Busch et al., 1996). According to the Centers for Disease Control
and Prevention, Lyme disease is usually diagnosed based on the presence of the
erythema migrans. Serological tests and PCR can also be used but the results are
unreliable (Murray and Shapiro, 2010). Lyme disease is treated with antibiotics
although some controversy exists over the duration of antibiotic treatment and the route
of antibiotic administration (Feder et al., 2007; Reid et al., 1998; Stricker, 2007). This
disease is typically treated with a 2-4 week course of the antibiotic doxycycline and
when treated early, is generally responsive to this treatment. Alternative antibiotics
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include amoxicillin and ceftriaxone (Wormser et al., 2006). Currently no vaccine for this
disease is available for human use and the sole method of prevention is limiting
exposure to the ticks that transmit the infection.
1.2 Borrelia
1.2.1 General characteristics
The genus Borrelia is made up of spirochetes that are helically shaped, motile,
and have two sets of periplasmic flagella in between the inner and outer membranes
that are attached to each end of the periplasmic cylinder (Barbour and Hayes, 1986)
(Figure 2). Although the Borrelia are said to be Gram-negative organisms based on the
presence of inner and outer membranes, they lack lipopolysaccharide (LPS) on their
cell surface. The Borrelia are microaerophilic and cultivated in a complex culture
medium supplemented with rabbit serum. These spirochetes need a rich medium and
are completely host-dependent due to the fact that they lack most de novo amino acid,
lipid, nucleotide, and enzyme cofactor synthesis (Fraser et al., 1997). Optimal growth
temperatures are between 33° and 37°C. These spirochetes can be easily viewed using
dark-field microscopy and typically range from 0.18 to 0.25 m in diameter and 4 to 30
m in length (Barbour, 1984; Ruzic-Sabljic et al., 2006). Members of this genus are
primarily enzootic and are able to cause several different diseases including Lyme
disease, epizootic bovine abortion, relapsing fever, and avian borreliosis, though only
Lyme disease and relapsing fever affect humans. There are two different forms of
relapsing fever, louse-borne relapsing fever caused by B. recurrentis and tick-borne
relapsing fever caused by B. hermsii and others. Lyme disease in humans is caused by
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Figure 2. Fluorescent micrograph of B. burgdorferi. The characteristic helical shape of
the spirochetes can be seen. Spirochetes were stained using BacLight Live/Dead
fluorescent stain. Live spirochetes stain green while dead spirochetes are red.
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three Borrelia species; B. burgdorferi, B. afzelii, and B. garinii. B. burgdorferi was the
first species to be associated with Lyme disease and can be found worldwide while B.
afzelii and B. garinii are only in Europe and Asia.
1.2.2 Borrelia genetics
The Borrelia have a very unique genome. All members possess a large linear
chromosome with various circular and linear plasmids. The full genome sequence of
the B. burgdorferi B31MI strain, a strain commonly used in the laboratory, was one of
the first bacterial genomes to be determined (Fraser et al., 1997). It was found that this
strain contains 1516 open reading frames encoded on a 910 kbp linear chromosome,
12 linear, and 9 circular plasmids, some of which appear to be prophage (Casjens et al.,
2000; Eggers and Samuels, 1999; Eggers et al., 2000; Fraser et al., 1997; Zhang and
Marconi, 2005). The plasmid content of different strains of B. burgdorferi can vary
greatly (Iyer et al., 2003; Terekhova et al., 2006) and can change between in vitro and
in vivo cultivation (Barbour, 1988; McDowell et al., 2001; Persing et al., 1994; Schwan
et al., 1988). Some plasmids are said to be universal and can be found in all B.
burgdorferi isolates (e.g., cp26) while others plasmids are required for infectivity but not
in vitro cultivation (e.g., lp25) (Byram et al., 2004; Grimm et al., 2004; Labandeira-Rey
and Skare, 2001; Labandeira-Rey et al., 2003; Marconi et al., 1993a; Purser and Norris,
2000; Tilly et al., 1997). Several of the genes encoded on these plasmids are housekeeping genes, but the majority of them are unique genes with unknown function
(Barbour and Garon, 1987; Barbour and Garon, 1988).
1.2.3 Enzootic life cycle
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The Borrelia are completely host-dependant and persist in nature through a
complex enzootic life cycle. For the Lyme disease spirochetes, this life cycle involves
ticks of the Ixodes ricinus complex and a wide variety of animals that serve as reservoir
hosts (Brown and Lane, 1992; Gern et al., 1998; Keirans et al., 1996). In the
northeastern and midwestern portions of North America, Ixodes scapularis (previously I.
dammini (Oliver et al., 1993)) is the primary tick vector while I. pacificus vectors the
spirochetes in the western United States (Lane et al., 1991). Ixodes ricinus is the
primary arthropod vector for species of Borrelia in Europe while I. persulcatus and I.
nipponensis serve as vectors in Asia (Hengge et al., 2003). Due to the fact that there is
no transovarial transmission of the Lyme disease spirochetes (Barbour and Hayes,
1986) animal reservoirs are necessary for maintenance of these bacteria in nature
(Figure 3). When larval ticks hatch out of eggs during the spring, they immediately
begin questing after a blood meal, which they usually take on a small mammal or bird.
It is often during this first blood meal that the ticks acquire a Borrelia infection. After
feeding to repletion the larvae molt into the nymphal stage and become dormant
through the winter. When the infected nymphs emerge in the late spring or early
summer of the next year, they will take a blood meal on another animal, possibly
transmitting the spirochetes. There is a wide range of competent reservoir hosts
including many species of small mammals and birds that can become infected during a
blood meal, a major one in North America being the white-footed mouse Peromyscus
leucopus (Gern et al., 1998; Keirans et al., 1996; Steere et al., 2004). After this blood
meal the ticks will molt into adults and feed on larger mammals such as deer. These
larger mammals are important in the enzootic cycle due to the fact that they can harbor
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Figure 3. Enzootic life cycle of B. burgdorferi. Shown is the life cycle of the tick vector,
Ixodes scapularis. Spirochetes cycle through Ixodes tick vectors and animal reservoir
hosts.
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http://www.cdc.gov/lyme/transmission/blacklegged.html
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greater numbers of tick vectors and aid in spreading them over larger areas. Humans
often contract the Lyme spirochetes through an encounter with infected nymphal ticks
but, due to the fact that they do not aid in the progression of the enzootic cycle, are
considered incidental hosts.
All the different hosts encountered by the Lyme Borrelia during their enzootic life
cycle present a variety of different environments to which the spirochetes must adapt.
One way that these bacteria are able to do this is through differential expression of
many outer surface lipoproteins (Boardman et al., 2008; Brooks et al., 2003; Caimano et
al., 2007; Revel et al., 2002; Rogers et al., 2009). A well characterized example of this
is the reciprocal expression of outer surface protein A (OspA) and outer surface protein
C (OspC).
1.3 Outer Surface Protein C (OspC)
1.3.1 General characteristics
Outer surface protein C (OspC) is an approximately 22 kDa surface exposed
lipoprotein (Fuchs et al., 1992) that is expressed by all of the Lyme Borrelia. This
protein is encoded on the universal plasmid cp26, which is a highly stable plasmid
present in all strains (Marconi et al., 1993a; Sadziene et al., 1993). The crystal
structure of OspC had been determined and shows that this protein is primarily alpha
helical in structure, containing five alpha helices that are connected by six loops (Eicken
et al., 2001; Kumaran et al., 2001b). Additionally, OspC forms homodimers (Figure 4A)
that are tethered to the outer membrane by an N-terminal tripalmitoyl-S-glycerylcysteine (Brooks et al., 2006). These homodimers are held together by hydrophobic
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Figure 4. Structure of OspC, conservation of residues, and location of putative ligandbinding domains. (A) Two OspC monomers are shown with the conserved to variable
residues indicated using a red to blue scale. (B) A VAST alignment is presented, using
CN3D 4.1 of type A in purple (1GGQ), type I in yellow (1F1M), and type E in gray
(1G5Z). (C) The OspC dimer is shown with the two putative ligand binding domains,
LBD1 and LBD2, indicated. Amino acid conservation is shown as in (A).
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interactions between the amino acids at the dimeric interface and are thought to be the
biologically active form of the protein, although higher order oligomers of this protein
may occur (Eicken et al., 2001; Zuckert et al., 2001). Expression of OspC is
upregulated by spirochetes residing in the midgut of ticks when they take a blood meal.
During this time, spirochetes migrate from the midgut to the salivary glands of the ticks
and enter the host. OspC remains expressed by spirochetes in the mammal for the first
few weeks of infection before it is downregulated (Fingerle et al., 1995; Masuzawa et
al., 1994; Schwan and Piesman, 2000). Numerous studies have implicated the
expression of OspC with the ability of the spirochetes to cause mammalian infection and
it has been shown that mutant strains of the Lyme Borrelia lacking OspC are unable to
cause infection by either the tick or needle inoculation route (Earnhart et al., 2010;
Fingerle et al., 2007; Gilmore and Piesman, 2000; Grimm et al., 2004; Pal et al., 2004;
Tilly et al., 2006; Tilly et al., 2007).
1.3.2 Phylogenetics
OspC is highly divergent in sequence. Over 30 different OspC phyletic types
have been identified (Earnhart and Marconi, 2007a; Seinost et al., 1999; Wang et al.,
1999) (Figure 5). Within an OspC type, amino acid sequences are >95% identical,
whereas between OspC types, identity ranges from 55-80% (Attie et al., 2007; Earnhart
and Marconi, 2007a; Wang et al., 1999). The sequence divergence that gives rise to
the different phyletic types is located in distinct, surface-exposed domains of the protein
(Earnhart et al., 2005; Earnhart et al., 2007) (Figure 4A). Even though there is such
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Figure 5. Phylogenetic tree of OspC type from the Lyme Borrelia. This phylogenetic
tree was generated by aligning the ospC residues 20 – 200 (lacking the signal
sequence) using Clustal X (http://www.clustal.org/) and NJ Plot (http://pbil.univlyon1.fr/software/njplot.html). Bootstrap values (1,000 trials) are shown at the nodes for
critical differentiation.
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0.1
Bb Szid - Szid (3)
Bb LDS79 - H (1)
Bb LDS101 - H (2)
Bb SI1 - L (3)
Bb 21347 - L (2)
Bb T255 - L (1)
Bb LDP116 - D (2)
Bb CA112A - D (1)
285
Bb OC10 - I (1)
Bb HB19 - I (6)
113
Bb LDP73 - B (6)
Bb PMi - B (2)
Bb PBre - B (3)
85
Bb DK7 - B (1)
Bb PSE - B (1)
Bb LDS106 - A (1)
Bb CA4 - A (1)
Bb B31 - A (34)
36
Bb LDP61 - A (1)
Bb MI2_bb - A (1)
Bb LDP63 - N (7)
Bb B356 - M (2)
316
Bb 2591 - M (1)
Bb cs5 - U (1)
338
Bb OC17 - U (1)
Bb 148 - U (1)
165
454
Bb N40 - E (6)
Bb OC7 - E (1)
307
Bb LDP74 - K (11)
Bb PAd - F (3)
Bb 21498son188 - F (1)
Bb P2351 - 72a (1)
Bb 72a - 72a (3)
Bg H13 - H13 (3)
180
Bg PWa - PWa (16)
256
Bg PBi - PWa (1)
997
Bg PHez - PHez (4)
Bg SL14 - PHez (1)
Bg SL10 - PFiM (1)
336
Bg K48 - PFiM (1)
Bg PFiM - PFiM (4)
251
Bg 261K - PLi (1)
Bg DK32 - PLi (1)
Bg DK29 - PLi (1)
Bg PLi - PLi (5)
275
Bg DK27 - PLi (1)
34
Bg Smar - Smar (4)
Ba VS461 - VS461 (3)
966
150
Ba ChY16p - DK15 (1)
359
Ba DK15 - DK15 (2)
Ba 2398 - HT25 (1)
Ba F579 - HT25 (1)
76
Ba HT25 - HT25 (2)
Ba KM4 - Pko (1)
Ba KK2 - Pko (1)
Ba KK5 - Pko (1)
27
Ba PBo - Pko (1)
Ba Pko - Pko (5)
Ba PGau - Pko (1)
Ba PWud - Pko (1)
Ba Spri - PLj7 (1)
Ba 56025 - PLj7 (2)
Ba PLj7 - PLj7 (3)
203
Bg HT22 - HT22 (1)
Bg 398 - HT22 (2)
Bg 1998 - HT22 (1)
82
Bg PMit - PMit (1)
Bg
BITS - PMit (2)
470
Bg PRef - PBes (1)
Bg
JEM2 - PBes (1)
356
Bg PBes - PBes (5)
Bg Ssob - PKi (2)
Bg PKi - PKi (1)
Bg PLa - PKi (2)
Bh YOR - Vtp

388

765
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sequence diversity between OspC types, these differences do not create structural
differences between types (Figure 4B). The domains that make up the variable portion
of OspC are also highly antigenic during mammalian infection and elicit a type-specific
humoral response. An individual strain only produces one OspC type which remains
stable during infection; however it has been demonstrated that multiple OspC types can
be found in tick, animal, and human samples from distinct geographic areas (Alghaferi
et al., 2005; Anderson and Norris, 2006; Earnhart et al., 2005; Lin et al., 2002; Wang et
al., 1999). Particular OspC types, specifically types A, B, I, and K, have been implicated
in the development of invasive disease symptoms in humans (Lagal et al., 2003;
Seinost et al., 1999) and further studies have suggested additional types which also
show this association (Alghaferi et al., 2005; Earnhart et al., 2005). It has also been
shown that certain OspC types tend to be commonly associated with different reservoir
hosts (Brisson and Dykhuizen, 2004).
1.3.3 Potential structure/function determinants
While it has been shown that expression of OspC is crucial for mammalian
infection, the actual function of this protein remains unknown. Although one study has
proposed that OspC itself has no actual function other than providing membrane
stability (Xu et al., 2008), other studies have proposed that OspC plays multiple roles in
the pathogenesis of the Lyme Borrelia. OspC may function in three distinct areas of
Borrelia pathogenesis: establishment of mammalian infection, reservoir host species
specificity/association, and tissue dissemination/ability to cause invasive disease
(Alghaferi et al., 2005; Brisson and Dykhuizen, 2004; Earnhart et al., 2005; Lagal et al.,
2003; Seinost et al., 1999). In the investigation of these different functions of OspC,
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several potential ligands have been proposed for OspC, including Salp15 and
plasminogen. Salp15, a tick-derived protein with immunomodulatory activity, is able to
bind OspC in vitro (Anguita et al., 2002; Das et al., 2001; Hovius et al., 2007). The
interaction between these two proteins may serve to protect the spirochetes from
antibody-mediated killing as they enter the host tissues (Hovius et al., 2008;
Ramamoorthi et al., 2005) and aid in the establishment of mammalian infection;
however, the ability of spirochetes to cause infection by the needle inoculation route
indicates that Salp15-binding is not the necessary function of OspC required to
establish infection. Another proposed OspC ligand is plasminogen. In other bacterial
species, plasminogen binding has been shown to be important in tissue penetration and
dissemination (Lagal et al., 2006; Lahteenmaki et al., 1998; Lahteenmaki et al., 2001).
OspC has been shown to bind plasminogen in vitro but the contribution of this
interaction is not known due to the presence of other plasminogen-binding proteins
expressed by the Borrelia (Brissette et al., 2009; Coleman et al., 1995; Grosskinsky et
al., 2009; Hovis et al., 2008; Lagal et al., 2006; Rossmann et al., 2007; Seling et al.,
2009). In order to decipher the function(s) of this protein in the absence of a ligand, a
novel approach must be employed.
1.4 Research Objectives
Several different portions of OspC have been theorized to play specific roles in
this protein‟s many theoretical functions. The OspC dimer has two solvent-accessible
domains that potentially could interact with a ligand(s). These domains have been
denoted as ligand binding domain 1 (LBD1) and ligand binding domain 2 (LBD2) (Figure
4C). LBD1 is a pocket formed by the juxtaposition of alpha helix 1 and 1` of the two

20

opposing OspC monomers. The residues that make up this domain are highly
conserved in sequence with some being invariant. LBD2 is located on the membrane
distal „crown‟ of OspC and contains the portion of OspC that gives rise to the different
phyletic types (Earnhart et al., 2010). In contrast to LBD1, the residues that make up
LBD2 are highly variable. In addition to these two binding domains, other portions of
OspC may also be important in its function. A cysteine residue at position 130 (C130)
may play a role in the formation of inter-dimeric bonds, forming higher order OspC
oligomers on the bacterial cell surface. Also the last ten amino acids (C10) of the Cterminal end of OspC are highly conserved in sequence and have been theorized to be
important in plasminogen binding and/or formation of important structural components,
(Lagal et al., 2006; Mathiesen et al., 1998b). Investigation of these different OspC
domains and residues could help lead to a better understanding of the function of this
critical Borrelia protein.
In this dissertation, the role of OspC in the establishment of mammalian infection,
host species specificity/association, and tissue dissemination were investigated through
the creation of many different OspC mutant strains of B. burgdorferi. The following
regions of OspC and their role in OspC function investigated:
(1) C130 – OspC harbors two cysteine residues, the N-terminal cysteine that
helps tether the protein to the cell surface and a cysteine at position 130. This
residue was mutated to an alanine in order to assess the role of C130 in the
formation of inter-dimeric bonds between OspC dimers on the cell surface,
resulting in higher-order oligomers. Additionally, the in vivo significance of
oligomer formation was assessed by infectivity and dissemination studies.
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(2) C10 – The last ten amino acids of OspC are highly conserved and have been
hypothesized to have a variety of functions. A mutant strain of B. burgdorferi was
created in which these residues have been deleted. This strain was used to
assess the role of these C-terminal residues in plasminogen binding, infectivity,
and host immune response to B. burgdorferi infection.
(3) LBD1 – The high level of conservation of residues within LBD1 indicate that
this region of OspC may play a role in the function of OspC that is necessary for
infection establishment. Specific residues within LBD1 were chosen for sitedirected mutagenesis in order to assess the role of this region of OspC in the
ability of the spirochetes to establish a mammalian infection.
(4) LBD2 – The most amino acid variability of OspC occurs in the LBD2 region.
This variability results in marked differences in electrostatic surface charge.
Specific residues within LBD2 were chosen for site-directed mutagenesis in order
to produce a more positive or negative charge on the LBD2 surface. The role of
surface charge on this portion of OspC in dissemination and spirochete
persistence was assessed.
(5) OspC type – Strains of Borrelia that express different OspC types also
contain other differences in their genome. In order to assess the role of OspC
type alone, whole ospC genes of different types were inserted into the same
genetic background. These mutants were then used to assess the role of OspC
type in host species association and infectivity.
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(6) OspC type A/PKo hybrids – OspC types A (from B. burgdorferi B31-5A4)
and PKo (from B. afzelii PKo) are expressed by strains that have been shown to
have differing host species specificity. B. burgdorferi mutants were generated
that express hybrids of OspC types A and PKo in order to assess the role of
different regions of OspC in host specificity.
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Chapter 2: Methods and Materials

2.1 Borrelia strains and nomenclature
All strains were cultured in Barbour-Stoener-Kelley (BSK) media supplemented
with 6% rabbit serum in a 37°C incubator with 5%CO2 (Table 1). Mutants generated for
this study were named with a common nomenclature that includes: (1) the name of the
parental strain (for all mutants in this document, the parental strain was B. burgdorferi
strain B31-5A4) (2) the gene targeted for mutagenesis and/or allelic exchange (in all
cases this gene was ospC), and (3) the amino acid, position, and substitution, OspC
type, or OspC hybrid chosen for allelic exchange (Table 2).
2.2 Site-directed mutagenesis of ospC
Site-directed mutations were introduced into the type A-ospC gene derived from
B. burgdorferi B31-5A4 by overlap extension using mutagenic primers (Table 3) as
previously described (Hovis et al., 2008). The following mutants were generated using
this method: B31::ospC (E61Q/E63Q), B31::ospC (E61Q), B31::ospC (E63Q),
B31::ospC (K60Y), B31::ospC (C130A), B31::ospC (N85G/D88N/E90Q), and B31::ospC
(H82D/N84D/N92D). Polymerase chain reaction (PCR) was used to amplify the type AospC gene with the introduced amino acid change(s) using the mutagenic primers in
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Table 1. Description of Borrelia isolates and strains
Species/Isolate
B. burgdorferi
B31MI (clone 5A4)
DRI-83a
DRI-40g
LDS79
Veery
B. garinii
PBi
B. afzelii
PKo
B. andersonii
MOD-1
MOK-3a
MOS-1b

Source

Geographic Origin

Ixodes scapularis
Dog skin
Dog skin
Human serum
Veery bird

New York
Rhode Island
Rhode Island
Baltimore, MD
Connecticut

Human CSF

Germany

Human Skin

Germany

Ixodes dentatus
Ixodes dentatus
Ixodes dentatus

Bollinger County, MO
Bollinger County, MO
Stodderd County, MO
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Table 2. Description of B. burgdorferi allelic exchange mutants
Allelic Exchange Mutant
B31ospC
B31ospC kanR
B31::ospC (wt)
B31::ospC (C130A)
B31::ospC (K60Y)
B31::ospC (E61Q/E63Q)
B31::ospC (E61Q)
B31::ospC (E63Q)
B31::ospC (type E)
B31::ospC (type F)
B31::ospC (type H)
B31::ospC (type M)
B31::ospC (type PBi)
B31::ospC (type PKo)
B31::ospC (type MOD1)
B31::ospC (type MOK3a)
B31::ospC (type MOS1b)
B31::ospC (H82D/N84D/N92D)
B31::ospC (N85G/D88N/E90Q)
B31::ospC (hybrid Aap)
B31::ospC (hybrid Apa)
B31::ospC (hybrid App)
B31::ospC (hybrid Paa)
B31::ospC (hybrid Pap)
B31::ospC (hybrid Ppa)
B31::ospC (200)

Missing
Plasmids

Vector
pCR2.1
pCAEV3
pCAEV1
pCAEV1
pCAEV1
pCAEV1
pCAEV1
pCAEV1
pCAEV1
pCAEV3
pCAEV1
pCAEV3
pCAEV1
pCAEV1
pCAEV1
pCAEV1
pCAEV1
pCAEV1
pCAEV1
pCAEV1
pCAEV1
pCAEV1
pCAEV1
pCAEV1
pCAEV1
pCAEV1

U
U
U
U

T
T

U
C, U
U
U
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Parental Strain
B31-5A4
B31-5A4
B31-5A4
B31-5A4
B31-5A4
B31-5A4
B31-5A4
B31-5A4
B31-5A4
B31-5A4
B31-5A4
B31-5A4
B31-5A4
B31-5A4
B31ΔospC kanr
B31ΔospC kanr
B31ΔospC kanr
B31-5A4
B31-5A4
B31-5A4
B31-5A4
B31ΔospC kanr
B31-5A4
B31ΔospC kanr
B31ΔospC kanr
B31-5A4

conjunction with full length ospC primers (OspC LIC +/-) at a final concentration of 0.75
pmol L-1. These reactions were run using 10 ng of B31-5A4 genomic DNA (isolation
described below) as template and Phusion Master Mix HF (Finnzymes) in 30 L
reactions in a MJ Research PTC-100 thermal cycler with the following conditions: 1
cycle of 98°C for 30 sec followed by 34 cycles of 98°C for 5 sec, 61°C for 10 sec, 72°C
for 30 sec, and finally 1 cycle of 72°C for 4 minutes with a indefinite 4°C hold. The
products from these reactions were then used as template for another round of PCR in
60 L reactions using Phusion Master Mix HF and full length OspC LIC +/- ospC
primers following the same parameters and conditions described above.
2.3 Ligase-independent cloning and sequencing of site-directed mutants
Site-directed mutant ospC genes were PCR amplified as described above. For
the introduction of different ospC types into the B31-5A4 type A-ospC background, the
desired types were PCR amplified from genomic DNA using full length gene primers
corresponding to the correct sequence of the different types (Table 3). The following
OspC types were chosen for allelic exchange into B31-5A4: (types A (from strain B.
burgdorferi B31-5A4), E (B. burgdorferi DRI83a), F (B. burgdorferi DRI40g), H (B.
burgdorferi LDS79), M (B. burgdorferi Veery), PKo (B. afzelii PKo), PBi (B. garinii PBi),
MOD-1 (B. andersonii MOD-1), MOK-3a (B. andersonii MOK-3a), and MOS-1b (B.
andersonii MOS-1b) (Table 2). Hybrid genes of OspC types A and PKo were
synthesized by an independent company (GenScript). After PCR amplification, the full
reactions were run out on a 1% GTG agarose gel and visualized with ethidium bromide.
The bands corresponding to the size of ospC were excised from the gel and the PCR
products purified using a Quiagen Gel Extraction kit. The ospC types, ospC hybrids,
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Table 3. Oligonucleotide primers
Primer

Description

Sequence

pCAEV1 Upstream (+)

pCAEV1 vector
construction
pCAEV1 vector
construction
pCAEV1 vector
construction
pCAEV1 vector
construction
pCAEV1 vector
construction
pCAEV1 vector
construction
pCAEV1 vector
construction
pCAEV1 vector
construction
pCAEV3 vector
construction
pCAEV3 vector
construction
Amplification of insert
Amplification of insert
Amplification of insert
Amplification of insert
Amplification of insert

CAGAATGAGTTACTTCTGGATGG

Transformation
confirmation
Transformation
confirmation
OspC sequence
confirmation
Deletion vector
construction
Deletion vector
construction
Deletion vector
construction
Deletion vector
construction
Amplification of OspC
for pET46
Amplification of OspC
for pET46
Mutagenic primer
Mutagenic primer
Mutagenic primer

CCTACGTTGTGATGAGACTTGATTT

pCAEV1 OspC 5' (-)
BspEI/MluI
pCAEV1 OspC 3' (+) BspEI
pCAEV1 BBB21 3' (-) AatII
Spec/Strep (+) SalI
Spec/Strep (-) AatII
pCAEV1 Downstream (+)
SalI
pCAEV1 Downstream (-)
MluI
flaB-GFP (+) XhoI
flaB-GFP (-) XhoI
Insert type A, F, M (+) BspEI
Insert type E, H (+) BspEI
Insert PKo (+) BspEI
Insert PBi (+) BspEI
Insert type A, E, F, H, M,
PKo, PBi (-) BspEI
Upstream confirm (+)
Spec/strep 3' (+)
Insert sequencing (+)
Deletion upstream (+)
Deletion upstream (-)
Deletion downstream (+)
Deletion downstream (-)
OspC (+) LIC
OspC (-) LIC
OspC E61Q/E63Q (+)
OspC E61Q/E63Q (-)
OspC K60Y (+)
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GTACGCGTTTTTCCGGAATTATTACAAGAT
ATAAATA
TCCGGATCAATATTATAAGATTAATTTGTTT
TAAA
GACGTCATCTCACATAAAACCAAAGAAACT
AC
GTCGACTAATACCCGAGCTTCAAGGA
GACGTCATTATTTGCCGACTACCTTGG
GTCGACTTTAAAAAGTTGTTAAATAGACTT
AACTAT
ACGCGTGGATATATGCAATCTTTAGTCCA
G
CTCGAGCCGGAGGAGTTATTTATAATAAAA
TAAAGAATTAC
CTCGAGGTGGCGGCCGCTCTAG
TCCGGAAAAGATGGGAATACATCTGCA
TCCGGAAAAGATGGGAATGCATCTGCA
TCCGGAAAAGGTGGGGATTCTGCA
TCCGGAGGGGATTCTGCATCTACTAATC
TCCGGATTAAGGTTTTTTTGGACTTTCTG

GGCGAGATCACCAAGGTAGTC
TAAAAAGGAGGCACAAATTAATG
GCAACAATCCAGTGTTTACAAAAACG
ACCGGTTCTGACGTCTAATTTGTGCCTCCT
TTTTATTTATGA
GACGTCGTTGTGGCAGAAAGTCCAAAAAA
ACC
ACCGGTGCTGTTTAACGATTTATTTGATAC
TTTGGGC
GACGACGACAAGATTAATAATTCAGGGAA
AGATGGG
GAGGAGAAGCCCGGTTTAAGGTTTTTTTG
GACTTTCTGC
GTGAAACAGGTTCAAGCGTTG
CAACGCTTGAACCTGTTTCAC
CAACGCTTCAACCTCATACAC

OspC K60Y (-)
OspC E61Q (+)
OspC E61Q (-)
OspC E63Q (+)
OspC E63Q (-)
OspC C130A (+)
OspC C130 (-)
OspC N85G/D88N/E90Q (+)

Mutagenic primer
Mutagenic primer
Mutagenic primer
Mutagenic primer
Mutagenic primer
Mutagenic primer
Mutagenic primer
Mutagenic primer

OspC N85G/D88N/E90Q (-)

Mutagenic primer

OspC H82D/N84D/N92D (+)

Mutagenic primer

OspC H82D/N84D/N92D (-)

Mutagenic primer

FlaB q-PCR primer (+)
FlaB q-PCR primer (-)
Nid1 q-PCR primer (+)
Nid1 q-PCR primer (-)
OspC 20 (+) LIC

q-PCR primer
q-PCR primer
q-PCR primer
q-PCR primer
Amplification of ospC
for pET vectors
Amplification of ospC
for pET vectors
Amplification of ospC
for pET vectors
Amplification of ospC
for pET vectors
Amplification pCAEV1
insert
Amplification pCAEV1
insert

OspC 210 (-) LIC
OspC 200 (+) LIC
OspC 200 (-) LIC
Insert type A 20 (+) BspEI
Insert type A 200 (-) BspEI

29

GTGTATGAGGTTGAAGCGTTG
GTGAAACAGGTTGAAGCGTTG
CAACGCTTCAACCTGTTTCAC
GTGAAAGAGGTTCAAGCGTTG
CAACGCTTGAACCTCTTTCAC
GCGGCTAAGAAAGCTTCTGAAAC
GTTTCAGAAGCTTTCTTAGCCGC
ATACACCAAAATGGTGGTTTGAATACCCAA
AATAATCAC
GTGATTATTTTGGGTATTCAAACCACCATT
TTGGTGTAT
GCTAAAGCTATTGGTAAAAAAAGAGATCAA
GATAATGGTTTGGATACCGAAAATGATCAC
GTGATCATTTTCGGTATCCAAACCATTATC
TTGATCTCTTTTTTTACCAATAGCTTTAGC
CAGGTAACGGCACATATTCAGATGC
CTTGGTTTGCTCCAACATGAACTC
CCAGCCACAGAATACCATCC
GGACATACTCTGCTGCCATC
GACGACGACAAGATTAATAATTCAGGGAA
AGATGGG
GAGGAGAAGCCCGGTTTAAGGTTTTTTTG
GACTTTCTGC
GACGACGACAAGATTCCTGTTGTGGCAGA
AAGTCC
GAGGAGAAGCCCGGTTTAGCTTGTAAGCT
CTTTAACTGAATT
TCCGGAAAAGATGGGAATACATCTGCA
TCCGGATTAGCTTGTAAGCTCTTTAACTGA
ATTAG

and site-directed mutant genes were then prepared for and annealed into the pET46
Ek/LIC vector. To accomplish this, the purified PCR products from above were first
treated with T4 DNA polymerase to generate single-stranded overhangs and then
annealed into the pET46 vector. The resulting plasmids were then transformed into
both Novablue and BL21 (DE3) strains of E. coli. Colonies were selected for ampicillin
resistance (50 g mL-1) and PCR with the OspC LIC +/- primer set was used to screen
the colonies for the presence of ospC. These PCR reactions were carried out using
GoTaq Master Mix (Promega) in 30 L reactions and the following PCR conditions:
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cycle of 95°C for 2 min followed by 34 cycles of 94°C for 15 sec, 50°C for 30 sec, 72°C
for 1 min, and finally 1 cycle of 72°C for 4 minutes with a indefinite 4°C hold. Several
colonies containing ospC were used to start 6 mL cultures in LB broth with ampicillin (50
g mL-1) and allowed to grown over night in a shaking 37°C incubator. The plasmids
were then isolated from the E. coli using a HiSpeed Plasmid Mini kit (Qiagen). All
procedures were performed as directed by the manufacturer (Novagen). The resulting
constructs were validated by automated DNA sequencing (MWG Biotech or GENEWIZ).
2.4 Generation of allelic exchange vectors
A master allelic-exchange vector designated as pCAEV1 was generated using a
pCR2.1 backbone (Figure 6A). A second allelic exchange vector called pCAEV3 was
constructed that is identical to pCAEV1 with the addition of the gene for production of
green fluorescent protein (gfp) (Figure 6B). To create pCAEV1 the following regions of
B. burgdorferi B31-5A4 cp26 were amplified: (1) region 5' of ospC (includes BbB18 and
extends through the signal sequence and first four amino acids of OspC; the amplicon
harbors 3' tandem BspEI and MluI sites), (2) region 3' of ospC (includes BbB20 and
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Figure 6. Schematic of allelic exchange vectors. The (A) pCAEV1 and (B) pCAEV3
vectors were generated as described in the text. Restriction sites necessary for
creation are shown.
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A

B

BbB18
1
7000

pCAEV1
+ ospC type A
7712 bp

6000

ScaI 5924

ospC signal sequence
BspEI 826

1

ospC

1000

ampR

BbB18

ospC signal sequence
BspEI 826

ospC

8000
BspEI 1402

amp

BbB20
BbB21
AatII 1719

BbB20
BbB21

R

ScaI 7059

7000

2000

strR

kanR

AatII 1710

pCAEV3
+ ospC type F
8847 bp

3000

R

MscI 5016

2000

6000

5000

kan

BspEI 1393

1000

PflFI 6187

3000

5000

4000
MluI 3775

SalI 2924
MluI 4910

BbB22

BbB22
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4000

gfp

R

str

BbB21 and flanking sequences; amplicon harbors 5' BspEI and 3' AatII sites) and (3)
region 3' of BbB21 (includes a portion of BbB22; amplicon harbors 5' SalI and 3' MluI
sites).

To allow for streptomycin/spectinomycin resistance selection, aadA was

amplified from pKFSS1 using primers with 5' SalI and 3' AatII sites (Frank et al., 2003)
(Table 3).

All amplicons were individually annealed into the pCR2.1 TOPO plasmid

and the plasmids were propagated in and isolated from Novablue E. coli as described
above. The plasmids were digested with the appropriate restriction enzymes to release
the inserts. The inserts were ligated into the plasmid carrying the 5' ospC-containing
fragment in the pCR2.1 TOPO vector and transformed into E. coli (C2925; New England
Biolabs). The pCAEV3 vector was created by amplifying the constitutively active gfp
gene from pCE323 and ligating it 5` of the streptinomycin resistance cassette in pCAEV1
(Eggers et al., 2006).
2.5 Allelic-exchange replacement of wild type ospC
To create the ospC allelic-exchange vectors, wild-type, ospC types, ospC
hybrids, and ospC genes with site-directed mutations (generated as detailed above)
were amplified with primers possessing 5' and 3' BspEI sites (Table 3). The amplicons
were cut with the appropriate restriction enzyme and ligated into pCAEV1 or pCAEV3.
The plasmids were propagated in Novablue E. coli cells (Novagen) and purified using
HiSpeed Plasmid Midi kits (Qiagen). All mutant strains of B. burgdorferi were made
using pCAEV1 with the exception of the B31-5A4 mutants containing OspC types F and
M, which were created using pCAEV3.
2.6 Transformation of B. burgdorferi
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The plasmids generated as described above were introduced into B. burgdorferi
B31-5A4 (kindly provided by Dr. Jon Skare) or B31ΔospC kanr (described below) by
electroporation essentially as previously described with some modifications (Samuels
and Garon, 1993; Samuels et al., 1994). B. burgdorferi B31-5A4 and B31ΔospC kanr
cultures were grown at 37°C to mid-log phase in BSK-H medium with 6% rabbit serum
(Sigma).

The cells were collected by a series of centrifugation steps. All

centrifugations were performed at 4°C and the cultures were always kept on ice. The
cultures were spun at 4,000 x g for 20 min, washed with 10 mL of cold Dulbecco‟s PBS
(dPBS), spun at 3,000 x g for 10 min, washed with 10 mL of cold EPS buffer (93 g L-1
sucrose, 15% glycerol), spun at 2,000 x g for 10 minutes, washed with 10 mL of cold
EPS buffer, and finally spun again at 2,000 x g and resuspended in 150 L of cold EPS.
The pCAEV1/3 plasmids containing the mutant ospC gene were linearized using MscI
or PflFI and ScaI-HF (New England Biolabs). A small amount each reaction was run on
a 1% agarose gel to ensure correct cutting. The linearized plasmids were purified
through two rounds of phenol/chloroform/isoamyl alcohol (25:24:1) (Fisher Scientific),
precipitated with ice cold absolute ethanol, washed with 70% isopropanol, allowed to
dry, resuspended in 6 L of mili-Q water, and quantified using UV spectrophotometery.
Twenty g of linearized plasmid was then mixed with 50 L of the cell suspension.
After 5 min on ice, the cells were electroporated (0.2 cm cuvette, 2.5 kV, 25 FD, 200
Ω), transferred to 10 mL BSK medium with 6% rabbit serum, and incubated overnight at
37°C (5%CO2). The culture volumes were increased to 50 mL with fresh BSK media,
streptomycin (50 g mL-1) was added, and the cultures were maintained at 37°C for 2 to
4 weeks.
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2.7 Subsurface plating of B. burgdorferi
Clonal populations of all transgenic strains were obtained by subsurface plating.
Briefly, 2% GTG agarose was autoclaved and placed in a 55°C water bath while BSK
media supplemented with 6% rabbit serum was placed in a 45°C water bath. The
bottom layers of plates were poured first with a final agarose concentration of 0.6%.
Three serial dilutions of the transformant cultures were prepared and mixed with the top
layer of the plates (final agarose concentration of 0.8%). The top layers were poured
over the bottom layers and the plates were allowed to cool and solidify before being
placed in sterile bags and incubated at 37°C (5%CO2) for 2-4 weeks until colonies
became visible. Clonal colonies were punched from plates using sterile pipettes, placed
in 2 mL of BSK-H media, and allowed to grow until dense. One mL of each clonal
culture was spun down (14,000 x g, 10 min) and cell pellets were resuspended in 40 mL
of mili-Q water. These pellets were boiled and used as template for PCR to determine
the plasmid contents of the transformants using plasmid-specific primer sets (McDowell
et al., 2001; Rogers et al., 2009). Additionally, to confirm the sequence of the DNA that
crossed over into cp26, the desired region was PCR amplified using Phusion Taq as
described above and sequenced (MWG Biotech or GENEWIZ).
2.8 Generation of B. burgdorferi B31ΔospC strr and B31ΔospC kanr strains
A pΔospC strr knockout vector was created by amplification of the upstream
(1000 bp) and downstream (1025 bp) regions of ospC with primers harboring
appropriate restriction sites (Figure 7A). The upstream amplicon contains tandem AatII
and AgeI sites at its 3' end while the downstream amplicon has 5' AatII and 3' AgeI sites
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Figure 7. Schematic of ospC knock-out vectors. The (A) pospC strr and (B) pospC
kanr vectors were generated as described in the text. Restriction sites are indicated.
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(Table 3). The amplicons were cloned into pCR2.1 and the plasmids were propagated
in and isolated from Novablue E. coli as described above. The plasmids were digested
with AatII and AgeI, and the downstream fragment was ligated to the upstreamcontaining plasmid. Finally, the aadA gene for streptomycin/spectinomycin resistance
was excised from the pKFSS1-AatII plasmid (Frank et al., 2003) and ligated between
the upstream and downstream sequences. The pΔospC kanr was created by excising
the aadA gene from pΔospC strr using AatII, digesting the PFligBaphIT7T kanamycin
resistance gene (kindly provided by Dr. Scott Samuels) with AatII, and ligating the two
together (Figure 7B). Transformation, subsurface plating and plasmid screening were
conducted as described above.
2.9 Assessment of growth curves
Either 10 or 15 mL tubes of BSK-H complete media were seeded with
approximately 5 x 105 cells mL-1 of actively growing cells.

Cultures for determining

LBD1 mutant growth curves were seeded lower than other transgenic strains.
Triplicate cultures were maintained at 37°C (5% CO2) and cell counts were conducted
each day using darkfield microscopy with an Olympus BX51 fluorescence microscope.
2.10 Production of recombinant OspC proteins
For recombinant protein production, BL21 (DE3) cells were transformed with the
pET46 Ek/LIC plasmids carrying wild type or mutated ospC genes as described above.
The pET46 plasmid utilizes an IPTG-inducible promoter and contains an N-terminal Histag to allow for protein purification.
(DE3) colonies contained ospC.

PCR was used to ensure that individual BL21

Once the correct insert was confirmed, protein was
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induced and purified.

For protein induction, an individual colony was grown in 100 mL

of LB broth containing ampicillin (50 g mL-1) in a 37°C shaking incubator. Once the
culture density reached an OD600 of between 0.5 and 0.8, protein expression was
induced with IPTG (1 mM).

After incubating for an additional 3 hours, cells were

collected by centrifugation (6,000 x g for 15 min), lysed using Bug Buster HT (Novagen),
and proteins purified by nickel chromatography using His-Bind resin (Novagen). The
purified proteins were then dialyzed against three changes of PBS and quantified by the
BCA assay (Pierce).
2.11 Generation of anti-OspC antiserum
To generate antiserum, C3H/HeJ mice were immunized with 10 µg of wild type
recombinant OspC protein adsorbed to Imject alum (Pierce), with boosts at weeks 4 and
6.

Serum was collected by tail bleed at weeks 5 and 7.

12 and blood was collected.
specific.

Mice were sacrificed at week

The serum was tested by immunoblot and shown to be

Week 7 blood had the greatest reactivity and was used in all analyses.

2.12 OspC immunoblot
To ensure that all mutant strains correctly produce OspC, Western blot analysis
was utilized. Cultures were cultivated at 27°C and then transferred to 37°C for 3 days to
induce ospC expression. The cells were then harvested by centrifugation (5,000 x g, 20
min), washed twice with PBS, and the equivalent of 1 OD600 of culture was suspended
in 150 L of reducing SDS-PAGE sample buffer (Laemmli and Favre, 1973). The cells
were then boiled and the cell lystates were subjected to SDS-PAGE using a 15% gel
(Criterion, Bio-Rad) (200 volts, 1 hr) and were transferred to PVDF membranes
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(Milipore) by electroblotting (100 volts, 1 hr). The membranes were blocked (5% milk in
PBS-T (PBS with 0.2% Tween 20)) for 1 hour before being screened with mouse-antiOspC (1:1,000). Washes with PBS-T occurred between each incubation. Antibody
binding was detected using peroxidase-conjugated goat-anti-mouse IgG (1:40,000) and
chemiluminescence (Supersignal West; Pierce).
2.13 Proteinase K proteolysis
To assess the presentation of OspC at the B. burgdorferi cell surface, strains
were cultivated at 27°C and then transferred to 37°C for 3 days to upregulate ospC
expression. The cells were harvested (5,000 x g, 20 min), washed twice with dPBS,
and the equivalent of 1 mL of culture at 0.3 or 0.2 OD600 was suspended in 1 mL of PBS
with or without proteinase K (20 mg mL-1). The cell suspensions were incubated at
22°C for 1 hr before phenylmethylsulfonyl fluoride (PMSF) was added (0.5 mg mL-1
methanol). The cells were then harvested by centrifugation (14,000 x g, 10 min) and
suspended in 120 µL of SDS-PAGE sample buffer. The cell lysates (2 µL) were
subjected to SDS-PAGE using 15% precast gels (Criterion, BioRad) and then
transferred to PVDF membranes (Millipore) by electroblotting. After being allowed to
dry, the membranes were blocked using 5% milk in PBS-T (PBS with 0.2% Tween 20)
for 1 hour before being screened with mouse-anti-OspC (1:20,000) or with mouse-antiFlaB (1:400,000). Washes with PBS-T occurred between each incubation. Antibody
binding was detected as described above.
2.14 Immunofluorescence assays (IFA)
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The distribution of OspC on Borrelia cells was assessed by immunofluorescent
microscopy. Cells were collected by centrifugation (3,000 x g, 10 min), washed with 10
mL of dPBS, spun again, and resuspended in 1 mL of dPBS. The OD600 of the cells
was determined and a 0.005 OD of each culture was suspended in 100 L of dPBS and
immobilized on slides (Superfrost Plus; Fisher). The slides were then blocked with 3%
BSA in PBS-T for 1 hour in a humidified chamber, washed with PBS-T, and probed with
mouse-anti-OspC antiserum (1:2,000) for 1 hour. Alexafluor 488 or 568-conjugated
rabbit-anti-mouse IgG (1:200) served as the secondary antibody. The slides were
mounted with Prolong Gold with DAPI (Invitrogen) and the cells visualized using an
Olympus BX51 fluorescence microscope.
2.15 Infectivity analyses
2.15.1 Subcutaneous C3H/HeJ mouse inoculation
To test infectivity of the different B. burgdorferi strains generated, C3H/HeJ mice
were inoculated with 1x104 spirochetes of each strain by subcutaneous injection. After
four weeks, the mice were euthanized and the heart, tibiotarsal joint, ear, bladder and
blood were harvested. Blood was spun down (14,000 x g, 15 min) to collect the serum
which was used for ELISA and Western blot analyses to assess the humoral response
generated by the host (described below). Portions of the ear and bladder biopsies or
portions of all organs collected were placed in BSK medium (supplemented with
rifampicin, fosfomycin, and amphotericin B) and incubated at 37°C under 5% CO2.
Each sample was visually assessed for spirochetes by darkfield microscopy after 2 and
4 weeks of incubation as a means of determining infectivity.
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2.15.2 Intradermal C3H/HeJ mouse inoculation
In order to investigate the effects of site-directed mutation of LBD2 on
dissemination, C3H/HeJ mice were inoculated intradermally with 1 x 104 spirochetes of
strains B31::ospC (wt) and B31::ospC (N85G/D88N/E90Q). The purpose of intradermal
inoculation was to restrict the inoculum and avoid passive dissemination of spirochetes.
Three mice were sacrificed 1, 3, 7, 14, and 21 days post-inoculation and blood, injection
site skin, distal skin approximately one cm from the injection site, heart, tibiotarsal joint,
ear and bladder tissues were collected.

Dissemination of spirochetes was assessed

by organ culture and serum was assessed for humoral response as described above.
2.16 DNA isolation
2.16.1 Genomic DNA isolation from Borrelia
To isolate genomic DNA from B. burgdorferi cells, a 50 mL culture was grown to
high density and the cells were collected by centrifugation (6,000 x g, 20 min) and
washed twice with PBS.

The cells were resuspended in 1 mL of TES solution (50 mM

Tris-HCl pH 8. 0, 40 mM EDTA, 25% sucrose) with 2% SDS and proteinase K (3 mg
mL-1) and incubated at 37°C for 45 minutes to lyse the cells. DNA was then extracted
using an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) and spun down at
room temperature (14,000 x g, 30 sec) to separate the layers. The upper aqueous
phase was transferred to a new 1.7 mL tube. To the aqueous phase, 3 volumes of cold
absolute ethanol and 1/10 volume of 7.5 M sodium acetate were added, mixed, and
chilled overnight at -80°C. The next day, the tubes were spun in a refrigerated
centrifuge (14,000 x g, 15 min) to pellet the DNA and the ethanol was removed. The
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resulting DNA pellets were then washed twice with 500 L of 70% ethanol and allowed
to air dry before being resuspended in 750 L of TE solution (10 mM Tris-HCl pH 8.0, 1
mM EDTA) and treated with RNase (0.03 mg mL-1), SDS (1%), and proteinase K (0.3
mg mL-1). After incubating for 30 minutes at 37°C, the DNA was again extracted with
phenol/chloroform/isoamyl alcohol (25:24:1), precipitated with absolute ethanol, and
allowed to chill overnight as described above. The pellets were then spun down
(14,000 x g, 10 min, 4°C) and washed with 500 L of 70% ethanol three times before
allowing the pellets to completely air dry. The DNA was resuspended in 300 L of miliQ water and quantified using UV spectrophotometery.
2.16.2 Total DNA isolation from animal tissues
To isolate DNA from mouse tissues, approximately 0.5 g of each tissue or organ
was digested with collagenase (2 mg mL-1) for 4 hours at 37°C and then with proteinase
K (0.1 mg mL-1) over night at 55°C. The samples were spun down to remove left over
animal debris and the supernatant was transferred to a clean 1.7 mL tube. DNA was
extracted from the supernatant by treatment with an equal volume of
phenol/chloroform/isoamyl alcohol (25:24:1) followed by centrifugation (14,000 x g, 30
sec) and removal of the top aqueous phase to a clean tube. This step was performed
twice. Next, the DNA was precipitated from the aqueous phase by using chilled
absolute ethanol and 1/10 volume of sodium acetate and allowed to sit at -80°C for 30
min. The DNA was then spun down (14,000 x g, 10 min) and the pellet was washed
with 70% ethanol twice, allowed to air dry, and resuspended in mili-Q water. The
concentration of DNA was quantified by UV spectrophotometery.
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2.17 Quantitative PCR analysis
Quantitative PCR (q-PCR) analysis was performed on LBD1 mutants (B31::ospC
E61Q/E63Q, B31::ospC (E61Q), B31::ospC (E63Q), and B31::ospC (K60Y)) and the
B31::ospC (C130A) mutant. For q-PCR, the Borrelia flaB gene and the mouse nidogen
1 (nid1) gene were amplified with Sybr Green PCR master mix (Applied Biosystems)
using an Opticon 2 DNA engine (MJ Research). PCR cycling conditions were: 94°C for
10:00, 40 cycles of 94°C for 15 sec, 56°C for 30 sec, 72°C for 30 sec, with fluorescence
reads following the extension cycle. Relative numbers of gene copies were determined
using a standard curve of Borrelia genomic DNA. To determine the extent of nonspecific, background amplification, qPCR was also conducted using DNA extracted from
the organs and tissues of uninfected mice. All samples were run in three replicates of
triplicates, and the organ-specific background amplification was subtracted from the
mean ratios. Statistical significance was assessed by ANOVA analysis of logtransformed data, with post-hoc testing by the Holm-Sidak method (SigmaPlot).
2.18 Enzyme-linked immunosorbant assay (ELISA)
The humoral response to inoculation was assessed by whole cell ELISA and
Western blot analyses. For the ELISA analyses, B. burgdorferi B31-5A4 cells were
pelleted, washed with PBS, suspended at 106 cells mL-1 (carbonate coating buffer) and
immobilized onto ELISA plates (100 µL well-1; 4°C; overnight) (Costar 3590). The
plates were blocked with 1% BSA in PBS-T blocking buffer for 2 hours at room
temperature. Serial dilutions of sera in blocking buffer were applied in duplicate and
allowed to incubate for 1 hour. Prior to application, sera were thoroughly mixed with a
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vortex. Antibody binding was detected using peroxidase-conjugated goat-anti-mouse
IgG (1:20,000) and ABTS chromogen. Titers were calculated as the inverse dilution
corresponding to one third of the plateau optical density.
2.19 Western blot
For Western blot analyses of the host immune response, B. burgdorferi B31-5A4
whole cell lysates were separated by SDS-PAGE (Criterion, Bio-Rad) and blotted to
PVDF membranes. The membranes were blocked with 5% nonfat dry milk in PBS-T
and screened with mouse serum (1:1000) for 1 hour at room temperature. Antibody
binding was detected using peroxidase-conjugated goat-anti-mouse IgG (1:40,000) and
chemiluminescence (SuperSignal West Pico; Pierce).
2.20 Circular dichroism analysis of OspC
Far-UV circular dichroism spectra of wild type and mutated recombinant OspC
proteins were measured at 20°C in a Jasco J-715 spectropolarimeter (Jasco, Easton,
MD, USA) (Chen et al., 1974). The protein samples (10 µM) were scanned in a 1 mm
path-length cuvette using a 1 nm bandwidth, 8 sec response time, and a scan rate of 20
nm/min. Three independent scans were made of each protein. Circular dichroism
spectra were subtracted from background (buffer alone) and converted from circular
dichroism intensity to molar ellipiticity (deg cm2 dmol-1).
2.21 Blue-native PAGE
To determine if the recombinant wild type, OspC site-directed mutant and OspC
hybrid proteins undergo dimerization, 1 μg of each protein was equilibrated in BN-PAGE
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loading buffer (15% glycerol, 50 mM Bistris pH 7.0) containing 0.02% Coomassie
brilliant blue G-250 (CBB-G250), and electrophoresed in a Novex Bis/Tris NativePAGE
gels 4-16% (Schagger et al., 1994). The cathode buffer (50mM tricine, 15mM Bis/tris,
pH 7.0) contained 0.002% CBB-G250 for the first half of the electrophoresis run (100
volts). Once the proteins entered the gel and ran approximately one third of the way
down the gel, the cathode buffer containing 0. 002% CBB-G250 was removed and
replaced with cathode buffer with no CBB-G250 and the gel was allowed to run to the
end (200 volts). The anode buffer was 50mM bis/tris pH 7.0. To visualize proteins, the
gel was stained using Coomassie Blue stain solution (R-250). The molecular mass of
the recombinant OspC proteins was interpolated from a standard curve generated with
NativeMark (Invitrogen) marker mix.
2.22 Plasminogen binding assay
Plasminogen binding by recombinant OspC was assessed by ELISA (Lagal et
al., 2006). ELISA plates (Costar 3590) were coated with 500 ng plasminogen (P7999,
Sigma) in carbonate buffer (pH 9.6). The wells were blocked with 1% BSA in PBS-T for
1 hour at room temperature. Recombinant OspC proteins (1 μg well-1 in blocking buffer)
were incubated in triplicate wells for two hours at room temperature. Secondary
detection of bound OspC was by mouse-anti-His-tag monoclonal antibody (1:1,000)
(Pierce), then by peroxidase-conjugated goat-anti-mouse IgG. Binding was quantified
using ABTS chromogen.
2.23 Structural modeling

46

Electrostatic surface charge maps of the site-directed mutants B31::ospC
(N85G/D88N/E90Q) and B31::ospC (H82D/N84D/N92D ) were created using Deep View
Swiss PdbViewer 4.0.1. The Poisson-Boltzman method was used and the color blue
denotes positive charge while red signifies negative charge. The prototypical OspC
model used in all structural models in this thesis is a surface projection of the IGGQ
OspC crystal structure (Kumaran et al., 2001b). All plasmids maps were generated
using BioEdit.
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Chapter 3: Results

3.1 In vitro assessment of B. burgdorferi OspC transgenic strains
3.1.1 Generation of mutant and control strains
A master allelic-exchange construct (designated as pCAEV1) was generated
(Earnhart et al., 2010) and ospC genes harboring amino acid substitutions, whole ospC
genes of different types, and ospC type hybrids were inserted. Selection was
accomplished with a streptomycin resistance (strR) cassette downstream of the BbB21
open reading frame. In pCAEV1, the modified ospC genes are under the transcriptional
control of a B. burgdorferi type A-ospC promoter (Alverson et al., 2003; Gilmore et al.,
2001; Marconi et al., 1993a; Xu et al., 2007; Yang et al., 2005). The endogenous cp26encoded wild type-type A ospC gene of B. burgdorferi B31-5A4 was replaced with the
mutated genes or with a wild type copy of ospC. This strain, designated B31::ospC
(wt), served as a control to verify that the general genetic manipulation procedures
employed and the expression of the antibiotic resistance cassette did not alter the
properties of B. burgdorferi B31-5A4 (detailed below). As a negative control, the cp26carried wild type copy of ospC was deleted from B. burgdorferi B31-5A4 and replaced
with a resistance marker using the pΔospC strr vector. An additional ospC knockout,
B31ospC kanr, was generated to expedite the generation of mutants.
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3.1.2 Assessment of plasmid content of transformant strains
B. burgdorferi B31-5A4 retains a large number of circular and linear plasmids that
are easily lost during transformation (Barbour, 1988; Casjens et al., 2000; Eggers and
Samuels, 1999; Eggers et al., 2000; Fraser et al., 1997; McDowell et al., 2001; Persing
et al., 1994; Schwan et al., 1988; Zhang and Marconi, 2005). After obtaining clonal
populations of each mutant or control, plasmid content was determined through PCR
using plasmid specific primer sets (data not shown) (Rogers et al., 2009). The full list of
allelic exchange strains and the plasmids lost can be found in Table 3. Sixteen of the
26 strains created retained the full B31-5A4 plasmid repertoire. The only plasmids lost
by any of the strains are cp9, lp5, and lp21. Strains B31::ospC (wt), B31::ospC (K60Y),
B31::ospC (E61Q/E63Q), B31::ospC (type E), B31::ospC (hybrid Apa), B31::ospC
(hybrid Ppa), and B31::ospC (C10) lost lp21 which has been shown to be is
inconsequential as it is not required for infectivity (Purser and Norris, 2000). Lp5, which
is missing from strains B31::ospC (type PKo) and B31::ospC (type MOD-1), contains
very few open reading frames, none of which encode genes necessary for infection
establishment. B31::ospC (hybrid Pap) is missing two plasmids, cp9 and lp21, neither
of which had any effect on the ability of this strain to cause mammalian infection.
3.1.3 Verification of sequence of the inserted ospC gene
Generating B. burgdorferi mutants is a difficult process due to many factors
including the slow growth rate of these organisms, how easily they lose plasmids, and
their low frequency of transformation. Additionally, during recombination, different
portions of the ospC genes located on pCAEV1/3 can cross over with the type A-ospC
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gene on cp26, making it difficult to introduce the exact changes desired. In order to
avoid this problem of incomplete crossover, the B31::ospC kanr mutant was developed.
Using this mutant, the whole correct ospC gene was inserted into cp26. Twenty of the
mutants in this study were generated by transformation of B31-5A4 while six strains
were created using the B31::ospC kanr mutant. Following transformation and
subsurface plating, the introduced copy of ospC was amplified from individual colonies
and the amplicons were sequenced to ensure that the desired sequence changes
occurred and that no other changes were introduced into the cp26 ospC gene.

No

sequence alterations, other than those intended, were detected in any of the allelic
exchange strains created.
3.1.4 Assessment of mutant strain growth rates
To ensure that the production of the mutant OspC proteins and the expression of
the antibiotic resistance cassette have no effect on the growth rate of the allelic
exchange strains, growth curves were determined by dark field microscopy. None of
the allelic exchange or ospC deletion mutants displayed a growth phenotype that
differed from the parental B31-5A4 strain (Figure 8A-G).
3.1.5 Verification of OspC production and surface exposure
Western blot, proteinase K digestion, and indirect immunofluorescence assays
(IFA) were used to demonstrate that all allelic exchange strains (except B31ΔospC) are
able to export, present, and distribute OspC on the cell surface in a manner consistent
with the parental B31 strain. Cells were exposed (or not exposed) to proteinase K,
which is known to cleave OspC from the outer membrane of Borrelia, and western blots
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Figure 8. Analysis of growth rate of OspC allelic exchange mutant strains. The rate of
growth of all mutants was determined by triplicate counts of each culture using dark field
microscopy. (A) C130A (B) C10 (C) LBD1 mutants (D) LBD2 mutants (E) OspC type
allelic exchange mutants (F) OspC type allelic exchanges from B. andersonii (G) OspC
A/PKo hybrids
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Figure 9. Analysis of OspC expression and presentation by allelic exchange strains.
Anti-OspC western blot was used to show OspC expression and proteinase K digestion
was used to show OspC cell surface presentation. (A) C130A (B) C10 (C) LBD1
mutants (D) LBD2 mutants (E) OspC type allelic exchange mutants
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of the cell lysates were screened with anti-OspC or anti-FlaB antisera, generated
against a periplasmic flagellar protein. The western blot of the cells not treated with
proteinase K show that all the mutant strains produce OspC (Figure 9A-F). Although
there appear to be differences in the expression levels of OspC between the allelic
exchange mutants and B31-5A4, these differences are most likely due to the typespecific nature of the immune response. The immunoblots were screened using antiOspC antiserum generated against OspC type A. This antiserum does not react
optimally to the different OspC types used for allelic exchange, accounting for the
differences in the band strengths. Exposure to proteinase K resulted in the loss of
detection of OspC, but not the periplasmic FlaB (Figure 9A-E). Digestion with
proteinase K showed that the allelic exchange mutants present OspC on the outer
membrane. Proteinase K analysis of the OspC type A/PKo hybrid strains is still
ongoing.
IFA analyses were used to assess the surface presentation and distribution of
OspC on the outer membrane of the transgenic strains. These analyses demonstrated
no visible differences in surface labeling patterns between the allelic exchange mutants
and B31-5A4 (Figure 10A-F). Additionally, the distribution of OspC on the surface of
these strains appears to be the same as B31-5A4. For strains B31::ospC (type F) and
B31::ospC (type M) an antibody tagged with red fluorescent protein was used due to the
fact that these mutants were created using pCAEV3 and already produce green
fluorescent protein. Based on the western blot, proteinase K, and IFA analyses, it can
be concluded that none of the ospC site-directed mutations, ospC type allelic
exchanges, ospC hybrid genes or the genetic manipulation of these strains influence
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Figure 10. Analysis of OspC surface presentation and distribution by allelic exchange
strains. IFA analysis was used as described in the text. (A) C130A (B) C10 (C)
LBD1 mutants (D) LBD2 mutants (E) OspC type allelic exchange mutants (F) OspC
A/PKo hybrids
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the production, surface presentation, and distribution of OspC. Additionally, deletion of
C10 does not appear to alter OspC expression or outer membrane export (Kumru et al.,
2011). In all of the above assays, no OspC signal was detected in the B31ΔospC strr or
the B31ospC kanr strain.
3.1.6 Assessment of dimerization ability of recombinant mutated OspC proteins
by blue-native PAGE
To determine if the LBD1 or LBD2 site-directed mutations influenced the ability of
OspC to dimerize, blue-native PAGE (BN-PAGE) analyses were performed (Schagger
et al., 1994) using recombinant protein. BN-PAGE analysis was also conducted using
recombinant C130A protein (r-OspC (C130A)) and will be discussed in greater detail
below. All site-directed mutant recombinant proteins efficiently dimerized and no
residual monomer was detected (Figure 11 inset, and data not shown). Collectively,
these analyses indicate that the substitutions introduced into OspC did not significantly
alter the secondary structure or ability of the mutant strains to dimerize.
3.1.7 Determination of alpha helical content of recombinant mutated OspC
proteins
The possible effect of each substitution of the LBD1 mutations and C130A on
OspC alpha helical content was directly assessed using circular dichroism
spectroscopic analyses (Figure 11). The estimated alpha helical content of the wild
type OspC protein (57.5% ± 4%) was found to be in agreement with that determined by
X-ray crystallography (~58%) (Eicken et al., 2001; Huang et al., 1999; Kumaran et al.,
2001b). Estimated percent alpha helical content values are indicated in Figure 11.
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Figure 11. Blue-native PAGE and circular dichroism analysis of the LBD1 mutants.
Circular dichroism analysis was used to analyse the helical content of the LBD1
mutants. BN-PAGE analysis (inset) demonstrated dimerization of all LBD1 mutants.
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While the alpha helical content of E61Q decreased to some degree, the circular
dichroism spectra of all other mutants were largely unaffected.
3.2 OspC residue C130 plays a role in oligomerization
3.2.1 Site-directed mutagenesis of B. burgdorferi OspC C130 and production of
C130A mutant r-OspC
Full length native OspC harbors two cysteine residues: an N-terminal tripalmitoyl
glyceryl modified Cys and C130 (Figure 12A). To determine if OspC dimers form
disulfide bonds that mediate higher order oligomerization in vivo, B. burgdorferi B31
ospC was replaced with ospC (C130A) by allelic exchange using the pCAEV1 vector.
Recombinant OspC was generated that lacked the leader sequence and the N-terminal
Cys residue. In the native protein, the modification of the N-terminal Cys prevents it
from playing a role in disulfide bond mediated oligomerization. To determine if C130 is
involved in OspC oligomerization, recombinant protein harboring a C130A substitution
was generated.
3.2.2 Assessment of oligomerization of OspC in vitro and in vivo
To assess the formation of disulfide bonds, r-OspC proteins and cell lysates of
each strain were analyzed by SDS-PAGE under reducing (β-mercaptoethanol) and nonreducing conditions (Figure 13). The monomeric native OspC and His-tagged r-OspC
proteins have masses of 20.3 kDa and 22 kDa, respectively. Under non-reducing
conditions, r-OspC (wt) existed in both monomeric and dimeric form, while r-OspC
(C130A) existed only in monomeric form (Figure 12B). Under reducing conditions only
monomers were detected (see conceptual model presented in Figure 12C-D). Dimeric
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Figure 12. Location of residue C130 and conceptual model of OspC oligomers. Figure
12A shows the hydrophobically bound OspC dimer (with residue C130 shown), which is
maintained under native conditions while in (B) the OspC monomer that is found under
denaturing conditions is shown. (C) Two OspC dimers can be covalently linked by
disulfide bonds formed between C130 residues. Under denaturing conditions, the
covalently bound OspC oligomers can be dissociated into monomers and covalently
bound dimers (D). These covalent dimers can only be dissociated into monomers
under reducing conditions.
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Figure 13. SDS-PAGE analysis of OspC oligomers under non-native conditions.
Recombinant wild-type (r-OspC(wt)) and C130A (r-OspC(C130A)) protein and Borrelia
cell lysates were separated using SDS-PAGE under conditions to reduce disulfide
bonds or nonreducing conditions, transferred to PVDF, and then probed with anti-OspC
antisera. The calculated molecular mass of the proteins are shown on the left.
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OspC was also detected in B31 and B31::ospC (wt) cell lysates when separated under
non-reducing conditions but not in the B31::ospC (C130A) cell lysate.
To determine if r-OspC dimers can oligomerize, r-OspC (wt) and r-OspC (C130A)
were separated under non-denaturing (both reducing and non-reducing) conditions
using BN-PAGE. Under non-reducing conditions five immunoreactive bands were
detected, all with molecular masses consistent with OspC oligomers from single dimers
to chains of 5 dimers (Figure 14). Only dimers maintained by hydrophobic interactions
were observed for the C130A protein. Under reducing conditions all OspC was dimeric
(Figure 14).
3.2.3 Infectivity and dissemination of strains expressing wild-type or C130A
OspC
The ability of each strain to establish infection in mice was assessed using
needle inoculation in two trials (5 mice per group). Four weeks post-inoculation, blood
was collected and tissue biopsies of the heart, tibiotarsal joint, ear, and bladder were
harvested and placed in media. In the first infection trial, only ear and bladder tissues
were placed in media for spirochete cultivation. Serum was collected from the blood
and used to determine the immune response mounted by the mice against the strains.
Positive cultures were found in all mice, except those infected with the negative control
B31ΔospC strain. Cultivation of each infectious strain from mouse tissues did not
reveal differences in dissemination patterns among strains (Table 4).
To assess the antibody response elicited by each strain (i.e., seroconversion),
anti-OspC and anti-B. burgdorferi IgG titers were determined by ELISA using r-OspC or
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Figure 14. BN-PAGE analysis of OspC oligomers under native conditions.
Recombinant wild-type (r-OspC(wt)) and C130A (r-OspC(C130A)) protein were
separated by blue native PAGE under reducing and nonreducing conditions, blotted to
PVDF, and probed using anti-OspC antiserum. Calculated molecular masses are
shown to the left.
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Table 4. Summary of culture results from tissues of mice inoculated with B31, ospC
transgenic control strains, and B31::ospC (C130A).
#Infected/Total
B31 (untransformed)
B31::ospC (wt)
B31::ospC (C130A)
B31ΔospC

Ear
10/10
10/10
5/10
0/10

Bladder
10/10
9/10
10/10
0/10
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Brain
1/5
0/5
0/5
0/5

Heart
3/5
5/5
4/5
0/5

Joint
1/5
3/5
2/5
0/5

Kidney
1/5
0/5
0/5
0/5

B. burgdorferi whole cells as the immobilized antigen. Whole cell and OspC-specific
IgG titers were similar for mice infected with B31, B31::ospC (wt) and B31::ospC
(C130A) cells (Figure 15).
3.3 The highly conserved C-terminal domain of B. burgdorferi OspC is not
required for OspC function in the mouse model
3.3.1 Deletion of the C-terminal domain of OspC and generation of recombinant
protein
The final ten amino acids (PVVAESPKKP) of OspC are highly conserved and
have been theorized to have multiple functions. In order to investigate the potential
functional roles and antigenicity of the conserved OspC C-terminus, ospC was replaced
in its native location with ospC lacking the C-terminal ten amino acids (C10) using the
pCAEV1 vector. Recombinant protein lacking the C10 amino acids was also generated.
3.3.2 Analysis of plasminogen binding by the B31::ospC (C10) strain
It has been hypothesized that conservation in the C10 sequence is due to a
functional constraint on sequence variation. Several functions for this domain have
been proposed. Lagal et al. (2006) hypothesized that the C-terminal lysine residues
of OspC are involved in binding plasminogen, which could aid in spirochete
dissemination by proteolysis of extracellular matrix proteins. In this study, a small
decrease in plasminogen binding by r-OspC (ΔC10) was noted when compared with
wild-type (Figure 16); however, it is clear that C10 is not required for plasminogen
binding.
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Figure 15. Immune response of mice inoculated with B31::ospC (C130A). ELISAs
were conducted using serum collected from mice four weeks post-inoculation. The
infecting strain is indicated along the x axis. The bars show the geometric mean
antibody titer while the triangles represent each individual mouse. The sera were
serially diluted, screened against whole B. burgdorferi 5A4 cells immobilized on ELISA
plates, and calculated as the inverse dilution corresponding to one-third of the plateau
optical density.
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Figure 16. Ability of B31::ospC (C10) to bind human plasminogen. Human
plasminogen was immobilized in ELISA plate wells and screened with His-tagged rOspC (wt) or r-OspC (ΔC10), with bound OspC detected by mouse anti-His-tag
antibody and peroxidase-conjugated goat-anti-mouse IgG.
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3.3.3 Assessment of infectivity of B31::ospC (ΔC10) in mice
Mathiesen et al. (1998b) suggested that C10 adopts a polyproline II helical
conformation – a secondary structure associated with protein-protein interactions and
bacterial adhesins (Brady et al., 2010). C10 also has sequence similarity with the
consensus recognition sequence for src homology domain 3 (SH3) proteins, which is a
potential bacterial virulence mechanism (Aitio et al., 2010; Ren et al., 1993). The
potential effect of disruption of these interactions on infection establishment was
necessarily accomplished by assessing the functional significance of the C10 domain
during infection. C3H/HeJ mice (n=5 per strain) were inoculated with control or
transgenic strains. After four weeks organs were harvested and used to assess
infectivity. Spirochetes were recovered from all mice infected with B31, B31::ospC (wt)
and B31::ospC (ΔC10) strains (Table 5). The negative control B31ΔospC strain was
non-infectious. Furthermore, there were no significant differences in induced anti-whole
Borrelia cell or anti-OspC IgG titers between the three infectious strains (Figure 17).
Thus, by this route of infection, the C10 domain is not required for OspC function.
3.4 OspC LBD1 plays a crucial role in the ability of B. burgdorferi to establish
mammalian infection
3.4.1 Site-directed mutagenesis of LBD1 of OspC of B. burgdorferi B31-5A4
To test the hypothesis that residues within LBD1 are involved in the in vivo
functional activities of OspC that are required for the establishment of infection in
mammals, residues K60, E61 and E63, which are charged, highly conserved, and
possess side chains that extend into the solvent accessible pocket of LBD1, were
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Table 5. Summary of culture results from tissues of mice inoculated with B31, ospC
transgenic control strains, and B31::ospC (C10).
#Infected/Total
B31 (untransformed)
B31::ospC (wt)
B31::ospC (ΔC10)
B31ΔospC

Ear
4/5
5/5
3/5
0/5

Bladder
5/5
5/5
5/5
0/5
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Figure 17. Analysis of the specific IgG titer of mice infected with B31::ospC (C10).
Serum was harvested from mice four weeks after needle inoculation. The sera were
serially diluted and screened against immobilized whole B. burgdorferi cells, r-OspC
(wt), r-OspC (ΔC10), or r-C10 peptide. Titers (indicated by triangles) were calculated as
the inverse dilution corresponding to one third of the plateau optical density. Geometric
mean titers are indicated by the bar.
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targeted for site-directed mutagenesis (Figure 18). These residues may serve as ligand
contact points or be important in defining the physiochemical properties of LBD1
required for ligand binding. Residues E61 and E63, which are negatively charged and
hydrophilic, and the positively charged and hydrophilic residue, K60, were replaced with
Q and Y residues (polar and hydrophilic), respectively. These changes were chosen
based on the reasoning that these substitutions would alter charge distribution, a key
parameter in ligand binding, without significantly affecting secondary structure. The
master allelic-exchange construct pCAEV1 was used to create B. burgdorferi strains
containing these site-directed mutations to OspC. Additionally, recombinant OspC
proteins harboring these mutations were generated.
3.4.2 Analysis of the infectivity of isogenic strains expressing LBD1 site-directed
mutations of OspC
To determine if the production of mutated OspC proteins affects the ability of
each strain to infect and disseminate, recombinant strains were administered to mice
using needle inoculation (n=5 mice per group). Ear punch biopsies and urinary
bladders were obtained 4 weeks after inoculation. Positive cultures were obtained from
all mice infected with B31-5A4 (untransformed control), B31::ospC (wt), B31::ospC
(E63Q) and B31::ospC (K60Y) (Table 6). In contrast, none of the mice injected with
B31ΔospC, B31::ospC (E61Q/E63Q) or B31::ospC (E61Q) yielded positive cultures
(Table 6). Since the sole genetic difference in strain B31::ospC (E61Q) relative to the
wild type parental strain was a single amino acid substitution, it can be concluded that
E61 is a critical determinant of OspC function in mammals.
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Figure 18. Location of residues chosen for LBD1 site-directed mutagenesis. A ribbon
diagram and surface projection of OspC is used to show the location of the residues
within LBD1 chosen for site-directed mutagenesis. The region containing LBD1 is
highlighted by a yellow box and magnified in the right half of the figure to show the
spatial location of these residues. Residue K60 is shown in red, E61 in blue, and E63 in
green.
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Table 6. Summary of culture results from tissues of mice inoculated with B31, ospC
transgenic control strains, and LBD1 site-directed mutants of OspC.
#Infected/Total
B31-5A4 (not transformed)
B31::ospC (wt)
B31ospCΔ
B31::ospC (K60Y)
B31::ospC (E61Q/E63Q)
B31::ospC (E61Q)
B31::ospC (E63Q)

Ear
5/5
5/5
0/5
4/5
0/5
0/5
5/5

Bladder
5/5
5/5
0/5
5/5
0/5
0/5
5/5
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3.4.3 Analysis of the immune response to strains expressing LBD1 site-directed
mutations of OspC
To determine if the inoculated mice developed a significant IgG response to B.
burgdorferi, anti-B. burgdorferi IgG titers were determined by ELISA. Immobilized B315A4 whole cells served as the test antigen. All strains that were infectious, based on
the cultivation results, displayed high level IgG titers whereas strains that yielded
negative cultivation results had low titers (Figure 19A). The low titer antibody response
observed in these strains most likely reflects a response to the inoculum (1x10 4 cells).
Immunoblot analyses yielded results consistent with the ELISAs (Figure 19B). Sera
from all infected mice reacted strongly with multiple B. burgdorferi proteins while no
significant reactivity of the sera derived from cultivation negative mice was observed.
The ELISA and immunoblot results are consistent with the infectivity data and serve to
further establish that specific site-directed substitutions within LBD1 result in a noninfectious phenotype.
3.4.4 Quantitative PCR (q-PCR) analysis of the dissemination of infectious strains
expressing LBD1 site-directed OspC mutations
To assess the influence of site-directed substitutions within LBD1 on
dissemination, spirochete burdens in tissues and organs of all infected mice were
determined by q-PCR. The parental B31-5A4 wild-type (untransformed), B31::ospC
(wt) and B31::ospC (E63Q) strains disseminated to bladder, heart and joint (Figure 20).
The numbers of B31::ospC (E63Q) spirochetes in the bladders of infected mice were
higher than those observed for all other strains; these differences were statistically
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Figure 19. Immune response of mice inoculated with LBD1 site-directed mutants.
ELISAs were conducted using serum collected from mice four weeks post-inoculation.
The infecting strain is indicated along the x axis. The bars show the geometric mean
antibody titer while the triangles represent each individual mouse. The sera were
serially diluted, screened against whole B. burgdorferi 5A4 cells immobilized on ELISA
plates, and calculated as the inverse dilution corresponding to one-third of the plateau
optical density.
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Figure 20. Spirochete burden in tissues of mice infected with LBD1 site-directed
mutants. Quantitative PCR was used to analyze the number of spirochetes in the
bladders, hearts, and joints of mice infected with LBD1 site-directed mutants. Organs
were harvested 4 weeks after needle inoculation and DNA was isolated from each
organ. The spirochete burden was determined by amplification of the B. burgdorferi
flaB gene normalized to copies of the mouse nid1 gene. The mean is represented by
the bar while each triangle represents an individual mouse. Statistical significance
(P<0.05) between the data sets is denoted by an asterisk (*).
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significant. No significant differences in spirochete burdens were observed among the
strains in tibiotarsal joints. Interestingly, very few B31::ospC (K60Y) spirochetes were
detected in the heart (Figure 20). However, the difference was statistically significant
only when compared with the wild type strain and hence some caution is in order in
assessing this data. Nonetheless, this observation is noteworthy in light of findings
suggesting that OspC is a determinant required for colonization of the heart (Antonara
et al., 2007).
3.5 Alteration of surface charge on LBD2 of B. burgdorferi OspC results in a
failure to persist in the mouse model
3.5.1 Site-directed mutagenesis of OspC LBD2 of B. burgdorferi B31-5A4
In order to assess the potential role of the LBD2 region of OspC in B. burgdorferi
infectivity and/or dissemination, site directed mutations were made within loops 2 and 3
in order to alter the surface charge of LBD2 (Figure 21). The amino acids selected for
substitution occur in the same positions in other OspC types. Two mutant strains of
were produced: B31::ospC (H82D/N84D/N92D) and B31::ospC (N85G/D88N/E90Q).
For the B31::ospC (H82D/N84D/N92D) strain, positive and polar residue H82 was
changed to an acidic and negative D residue while the polar residues N84 and N92
were also changed to D. These mutations resulted in an expansion of negative charge
across the dome of OspC (Figure 22). For the B31::ospC (N85G/D88N/E90Q) mutant,
residue N85 was changed to G, negative and acidic residue D88 was changed to a
neutral N, and acidic residue E90 was changed to a neutral Q.

These mutations

resulted in a loss of much of the negative charge across LBD2 which
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Figure 21. Alignment of OspC loop 2/3 region showing residues chosen for LBD2 sitedirected mutagenesis. Three residues each were chosen for mutation in the region of
loop 2 – loop 3 of OspC for the two LBD2 mutants. The residues chosen for mutation in
the type A ospC gene were substituted with amino acids that occur in the same in at
least one other OspC type. Residues chosen for mutation are highlighted with boxes.
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Figure 22. Electrostatic charge maps of LBD2 site-directed mutants. The OspC dimer
is shown in two rotations and from the top with the calculated electrostatic potential
superimposed on the molecular surface using Swiss-PdbViewer 4.0.1. Negative charge
is depicted by the color red while positive charge is shown with blue. The charge maps
for the mutants were super imposed on the structure of wild-type type A OspC.
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allowed for an expansion of the positive charge along the surface of the whole of OspC
molecule (Figure 22). Recombinant OspC protein was generated containing these sitedirected mutations. For the rest of this manuscript, these two mutants will be referred to
as B31::ospC (HNN) and B31::ospC (NDE).
3.5.2 Analysis of the infectivity of isogenic strains expressing OspC LBD2 sitedirected mutations
In order to test the infectivity of the LBD2 mutant strains, mice (n=5 per strain)
were injected subcutaneously with the B. burgdorferi strains B31 wild-type, B31ospC,
B31::ospC (HNN) and B31::ospC (NDE). Ear and bladder tissues were collected four
weeks post-injection and placed in BSK complete medium for spirochete culture.
Spirochetes were cultivated from organs of mice inoculated with all strains except
B31ΔospC strr and B31::ospC (NDE). Mice infected with these two strains produced no
spirochetes from either the ear or bladder tissues (Table 7).
3.5.3 Analysis of the immune response to strains expressing OspC LBD2 sitedirected mutations
ELISA and western blot analysis were used to investigate the humoral immune
response produced by mice inoculated with the B. burgdorferi strains described above.
All strains found to be infectious displayed high IgG titers. Despite the absence of
spirochetes cultured from organs, mice inoculated with B31::ospC (NDE) produced
antibody titers that were approximately one log fold lower than those of the wild typeinfected mice and much higher than those of the noninfectious B31ΔospC strr (Figure
23A). Western blot analysis similarly showed antibody generated against B31::ospC
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Table 7. Summary of culture results from tissues of mice inoculated subcutaneously
with B31, ospC transgenic control strains, and LBD2 site-directed mutants of OspC
#Infected/Total
Strain
B31
B31::ospC (wt)
B31ΔospC
B31::ospC (H82D/N84D/N92D)
B31::ospC (N85G/D88N/E90Q)

Ear
4/5
5/5
0/5
5/5
0/5

Bladder
5/5
5/5
0/5
5/5
0/5
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Figure 23. Immune response of mice inoculated subcutaneously with LBD2 sitedirected mutants. ELISAs were conducted using serum collected from mice four weeks
post-inoculation. The infecting strain is indicated along the x axis. The bars show the
geometric mean antibody titer while the triangles represent each individual mouse. The
sera were serially diluted, screened against whole B. burgdorferi 5A4 cells immobilized
on ELISA plates, and calculated as the inverse dilution corresponding to one-third of the
plateau optical density.
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(NDE) binding to B31-5A4 cell lysate, indicating that, while uncultivable from ear and
bladder tissues, this mutant was able to elicit an immune response (Figure 23B).
3.5.4 Analysis of dissemination/persistence of isogenic strains expressing OspC
LBD2 site-directed mutations
The inability to culture strain B31::ospC (NDE) from ear and bladder tissues while
still detecting an antibody response against this mutant posed the question of whether
this result was due to lack of dissemination of the mutant to these tissues or an inability
of this mutant to persist in the mouse for 28 days. In order to answer this question,
intradermal inoculations were performed. Mice were inoculated with strains B31::ospC
(wt) and B31::ospC (NDE). Culture of organs taken from 1, 3, 7, 14, and 21 days postinoculation showed that mutant B31::ospC (NDE) was able to disseminate to all organs
harvested but between days 7 and 14, this mutant was no longer cultivable (Figure 24).
This result indicates that the B31::ospC (NDE) mutant is unable to persist in the mouse
model.
3.6 Allelic exchange replacement of ospC demonstrates the role of OspC phyletic
type in establishment of murine infection
3.6.1 Allelic exchange of the ospC genes of different types
To assess the role of OspC type in infection establishment in mice, a number of
allelic exchanged strains were created which express different ospC phyletic types.
Nine different types were chosen for allelic exchange: OspC type E from B. burgdorferi
strain DRI-83a, OspC type F from B. burgdorferi strain DRI-40g, OspC type H from B.
burgdorferi strain LDS79, OspC type M from B. burgdorferi strain Veery, OspC type PBi
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Figure 24. Analysis of dissemination/persistence of LBD2 site-directed mutants. Mice
were intradermally inoculated with LBD2 site-directed mutants. Three mice per time
point were sacrificed and multiple organs were harvested and placed in media to assess
infectivity.
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from B. garinii strain PBi, OspC type PKo from B. afzelii strain PKo, OspC type MOD-1
from B. andersonii strain MOD-1, OspC type MOK-3a from B. andersonii strain MOK3a, and OspC type MOS-1b from B. andersonii strain MOS-1b (Tables 1 and 2).
Controls included previously described strains in which the wild type gene (type A) was
introduced in the same genetic context as the mutant (B31::ospC (wt)), and in which the
gene was deleted entirely (B31ΔospC strr) (Earnhart et al., 2010). An alignment of the
different allelic exchange strains shows the amino acid variability between the OspC
types chosen for analysis in this study (Figure 25). Following transformation,
streptomycin selection, and establishment of a clonal line by subsurface plating, ospC
was confirmed by DNA sequencing and the plasmid content of each transgenic strain
was determined.
3.6.2 Analysis of infectivity and dissemination of strains expressing wild-type or
OspC type switch mutants
In order to test infectivity of the transgenic strains, mice (n=5 per group) were
inoculated and four weeks later organs were harvested. Additionally, mice were
inoculated with seven of the wild type strains in order to confirm the infectivity of these
strains. Spirochetes were re-cultivated for all transgenic strains except B31::ospC (type
F) and B31::ospC (type MOS-1b) in which only a single mouse was culture positive, and
B31::ospC (type PKo), B31::ospC (type MOD-1), and B31ΔospC strains, in which none
were positive. Positive cultures were obtained from all mice infected by wild type
strains, except B. afzelii PKo and B. andersonii MOD-1, MOK-3a, and MOS-1b in which
none were positive (Table 8).
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Figure 25. Alignment of OspC types chosen for allelic exchange into the B31-5A4
background.
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Table 8. Summary of culture results from tissues of mice inoculated with parental
strains, ospC transgenic control strains, and B31::ospC strains expressing different
ospC types.
#Infected/Total
Ear

Bladder

Wildtype strains
B31(type A)
DRI-83a (type E)
DRI-40g (type F)
PKo (type PKo)
PBi (type PBi)
MOD-1 (type MOD-1)
MOK-3a (type MOK-3a)
MOS-1b (type MOS-1b)

5/5
5/5
5/5
0/5
5/5
0/5
0/5
0/5

5/5
4/5
5/5
0/5
2/5
0/5
0/5
0/5

Transformed strains
B31::ospC (wt)
B31::ospC (type E)
B31::ospC (type F)
B31::ospC (type H)
B31::ospC (type M)
B31::ospC (type PKo)
B31::ospC (type PBi)
B31::ospC (type MOD-1)
B31::ospC (type MOK-3a)
B31::ospC (type MOS-1b)
B31ΔospC

5/5
4/5
1/5
5/5
5/5
0/5
4/5
0/5
4/5
1/5
0/5

5/5
5/5
1/5
4/5
5/5
0/5
5/5
0/5
3/4
1/5
0/5
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3.6.3 Analysis of the immune response to strains expressing wild-type or OspC
type switch mutants
The antibody response to infection was quantified by whole cell ELISA.
Antibody titers for sera from mice inoculated with transgenic strains were similar in all
mice except those infected with B31::ospC (type PKo), B31::ospC (type MOD-1),
B31::ospC (MOS-1b), and B31ΔospC strr (Figure 26). No mouse inoculated with
B31::ospC (type PKo) seroconverted. The mice inoculated with strains B31::ospC
(MOD-1) and B31::ospC (MOS-1b) seroconverted but at a lower level than mice
inoculated with other strains. The titer for the single culture positive mouse infected with
B31::ospC (type F) was approximately a log-fold higher than the titer from the culture
negative mice, though the titer for these mice was similar to that seen in sera from
culture positive animals infected with other strains.
In the analysis of titers produced by mice inoculated with B. afzelii PKo wild type,
one mouse had a titer similar to that seen in mice inoculated with strains known to be
infectious (e.g., B31). PCR amplification and sequencing of ospC from DNA extracted
from tissue in that mouse demonstrated the presence of type A and E ospC. Thus, this
infection was likely due to the establishment of infection in that mouse by other strains
in the non-clonal primary B. afzelii PKo isolate. It should be noted that these strains
were not re-cultivated from this mouse. All mice inoculated with B. andersonii wild type
strains showed no seroconversion.
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Figure 26. Immune response of mice inoculated with OspC type allelic exchange
mutants. ELISAs were conducted using serum collected from mice four weeks postinoculation. The infecting strain is indicated along the x axis. The bars show the
geometric mean antibody titer while the triangles represent each individual mouse. The
sera were serially diluted, screened against whole B. burgdorferi 5A4 cells immobilized
on ELISA plates, and calculated as the inverse dilution corresponding to one-third of the
plateau optical density.
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3.7 Investigation of the domain of OspC that influences host specificity of the
Lyme Borrelia
3.7.1 Design and allelic exchange of OspC type A/PKo hybrids
In order to determine the domain of OspC responsible for host species
specificity, mutant strains of B. burgdorferi were generated that express hybrids of
OspC types A and PKo. OspC was divided into three portions, LBD1/OspC core (amino
acids 19-78, 94-140, and 158-210), LBD2a (amino acids 79-93), and LBD2b (amino
acids 141-157) (Figure 27 A-B). Complete ospC genes were produced that contained
all possible combinations of these three portions. Three mutants each contained the
core of either ospC type A or PKo. The different hybrids were denoted with a common
nomenclature that included the first letter of the OspC type that comprised the core,
either an upper case A or P, followed by the first letter (lower case) of the type that
made up the LBD2a portion and then the first letter of the type of the LBD2b region. For
example, B31::ospC (hybrid Aap) contains the OspC type A core and LBD2a regions
and the OspC type PKo LBD2b region (Figure 27 C). The complete genes were ligated
into the pCAEV1 vector and transformed into B. burgdorferi to generate OspC hybrid
mutant strains (Earnhart et al., 2010). Recombinant protein of the different hybrids was
also generated.
3.7.2 Analysis of infectivity of OspC type A/PKo hybrid strains in mice
To determine which portion(s) of OspC is necessary for infectivity in mice,
CeH/HeJ mice were inoculated subcutaneously with spirochetes by needle injection.
Four weeks post-inoculation the mice were sacrificed and the ear, heart, bladder and
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Figure 27. Design of OspC type A/PKo hybrid genes. (A-B) OspC was divided into
three portions, LBD1/OspC core (amino acids 19-78, 94-140, and 158-210), LBD2a
(amino acids 79-93), and LBD2b (amino acids 141-157). Boxes and an OspC model
are used to highlight the two portions of LBD2 chosen. (C) Schematic of the OspC
hybrids created.
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Table 9. Summary of culture results from tissues of mice inoculated with ospC
transgenic control strains and B31::ospC (A/PKo) hybrid strains.
#Infected/Total
Strain
B31::ospC (wt)
B31::ospC (type PKo)
B31::ospC (hybrid Aap)
B31::ospC (hybrid Apa)
B31::ospC (hybrid App)
B31::ospC (hybrid Paa)
B31::ospC (hybrid Pap)
B31::ospC (hybrid Ppa)

Ear
4/4
0/4
2/4
4/4
4/4
0/4
4/4
4/4

Bladder
4/4
0/4
2/4
2/4
3/4
0/4
2/4
2/4

a

Heart
2/4
0/4
2/4
4/4
2/4
0/4
3/4
4/4

Joint
3/4
0/4
2/4
2/4
3/4
0/4
3/4
1/4

Totala
4/4
0/4
4/4
4/4
4/4
0/4
4/4
4/4

Total mice infected column included due to the fact that organ data does not
accurately depict number of infected animals.
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tibiotarsal joint tissues were harvested and cultured in order to assess infectivity. The
strains B31::ospC (type PKo) and B31::ospC (hybrid Paa) showed no spirochetes in any
of the organs cultivated (Table 9). All other strains were able to be cultivated out of at
least one organ cultured.
3.7.3 Analysis of immune response to OspC A/PKo hybrid strains generated by
mice.
ELISA using immobilized whole B. burgdorferi cells were used to assess the
humoral response generated by both mice and hamsters inoculated with the OspC type
A/PKo hybrid mutants. All mutants that were culture positive also displayed high IgG
titers. Mice inoculated with B31::ospC (type PKo) had a detectable but extremely low
titer while mice inoculated with B31::ospC (hybrid Paa) produced a titer that was similar
to infectious strains (Figure 28).
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Figure 28. Immune response of mice inoculated with OspC type A/PKo hybrids.
ELISAs were conducted using serum collected from mice four weeks post-inoculation.
The infecting strain is indicated along the x axis. The bars show the geometric mean
antibody titer while the triangles represent each individual mouse. The sera were
serially diluted, screened against whole B. burgdorferi 5A4 cells immobilized on ELISA
plates, and calculated as the inverse dilution corresponding to one-third of the plateau
optical density.
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Chapter 4: Discussion

4.1 OspC residue C130 plays a role in oligomerization
OspC is an important virulence factor for the Lyme Borrelia (Earnhart et al., 2007;
Earnhart and Marconi, 2007b, c; Grimm et al., 2004; Pal et al., 2004; Stewart et al.,
2006; Tilly et al., 1997; Tilly et al., 2006; Tilly et al., 2007). Efforts to define the function
of OspC have been significantly enhanced by recent analyses of OspC structurefunction relationships (Earnhart et al., 2010; Eicken et al., 2001; Kumaran et al., 2001a;
Kumaran et al., 2001b; Wang et al., 1999). A postulate that has not yet been tested is
that OspC may form functionally and immunologically significant arrays in the Borrelia
outer membrane (Lawson et al., 2006). While freeze-fracture microscopic analyses
indicate the existence of membrane protein arrays in B. burgdorferi, the composition of
these arrays have not yet been determined (Radolf et al., 1994). Here we test the
hypothesis that hydrophobic based-OspC dimers form biologically relevant higher order
oligomers that result from interdimeric disulfide bonding mediated by residue C130. To
assess this, a recombinant site-directed OspC mutant protein (r-OspC (C130A)) and a
B. burgdorferi strain that produces this site-directed mutant (B31::ospC (C130A)) were
generated and OspC oligomerization tested (Earnhart et al., 2011). Recombinant wild
type OspC formed oligomeric chains of two to five dimers (Figure 14). Formation of
these oligomers was eliminated by reducing conditions and proved to be strictly
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dependent on C130 (Figure 13). While technical limitations prevented the direct
assessment of OspC oligomeric length at the Borrelia cell surface, the occurrence of
disulfide bonded OspC at the cell surface and the data obtained with recombinant
proteins support the notion that disulfide-dependent oligomers form in vivo.
Direct functional assays for OspC have not yet been defined. However, due to
the essential nature of OspC, mutations that perturb critical determinants of the protein
can be identified by assessing infectivity in mice. To determine if OspC oligomerization
is required for OspC to carry out its in vivo function, wild type and B31::ospC (C130A)
strains were inoculated into mice and infectivity and dissemination assessed. While
substitution of C130 with Ala prevents higher order oligomerization, it did not abolish
infectivity as inferred by seroconversion and the ability to cultivate spirochetes from ear
punch biopsies of inoculated mice. Dissemination was assessed by cultivation of
biospy samples harvested at sites distal from the original inoculation site (Table 4). An
apparent difference in dissemination potential was not observed. These analyses
definitively demonstrate that disulfide bond mediated oligomerization is not required for
survival and dissemination within the mammalian host.
In summary, it can be concluded that OspC is able to form oligomers on the cell
surface of B. burgdorferi. It has also been shown through this study that disulfide bond
mediated oligomerization is not required for OspC to function in the establishment of
infection, dissemination or the generation of a robust and potentially productive antibody
response(Earnhart et al., 2011).
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4.2 The highly conserved C-terminal domain of OspC is not required for OspC
function in the mouse model
The highly conserved C-terminal 10 amino acids of OspC have been
hypothesized to have multiple functions. Here the potential functional role and
antigenicity of the conserved C-terminus of OspC is investigated. To accomplish this,
ospC was replaced in its native location with ospC lacking the C-terminal ten amino
acids (C10). The resultant B31::ospC (ΔC10) strain was screened for plasmid loss,
growth rate, and surface expression and presentation of OspC, all of which are similar
to wild type. It can be concluded that deletion of C10 does not alter expression or
export of OspC to the outer membrane (Kumru et al., 2011) (Figures 9 and 10).
Targeted mutations in conserved, surface-exposed OspC residues have been
successfully used to define structurally and functionally important domains and residues
(Earnhart et al., 2010; Earnhart et al., 2011). In this study it is hypothesized that
conservation in the C10 sequence (PVVAESPKKP) is due to functional constraints on
sequence variation. Several functions for this domain have been proposed. It has been
suggested that C10 adopts a polyproline II helical conformation (Mathiesen et al.,
1998b) – a secondary structure associated with protein-protein interactions and
bacterial adhesins (Brady et al., 2010). C10 also has sequence similarity with the
consensus recognition sequence for src homology domain 3 (SH3) proteins – a
potential bacterial virulence mechanism (Aitio et al., 2010; Ren et al., 1993). Lagal et al.
(2006) hypothesized that the C-terminal lysine residues are involved in binding
plasminogen. Cell surface associated plasminogen could aid in spirochete
dissemination through the proteolysis of extracellular matrix proteins. To determine if
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C10 participates in plasminogen binding, r-OspC (ΔC10) was used in binding assays to
determine if the C10 amino acids facilitate this interaction (Figure 16). Deletion of the
C10 domain did not have a significant impact on plasminogen binding, therefore it can
be concluded that C10 is not required for plasminogen binding.
To determine if C10 domain is required for OspC function in vivo, mice were
inoculated with control or transgenic strains. All mice inoculated with B31, B31::ospC
(wt) and B31::ospC (ΔC10) strains yielded positive cultures. As expected, the negative
control B31ΔospC strain was non-infectious. The immune response generated by mice
inoculated with these strains confirmed infectivity. Thus, by this route of infection, the
C10 domain is not required for OspC function in vivo (Table 5).
OspC is of considerable interest as a diagnostic antigen because of its early and
high level expression during mammalian infection. A number of studies have used
peptides based on the conserved C-terminal 7 to 10 amino acids of OspC as an
immobilized antigen to detect early Borrelia-specific immune responses (Bacon et al.,
2003; Du et al., 2007; Jobe et al., 2003; Jobe et al., 2008; Lovrich et al., 2005; Lovrich
et al., 2007; Mathiesen et al., 1996; Mathiesen et al., 1998a; Mathiesen et al., 1998b;
Nagel et al., 2008; Panelius et al., 2002; Porwancher et al., 2011; Qiu et al., 2000). The
majority of these studies have found an early, predominantly IgM response to this
epitope, and it has been suggested that this may be due to a T-cell-independent
response mediated by the presentation of this epitope in a repetitive fashion at the cell
surface (Du et al., 2007; Earnhart et al., 2011; Mathiesen et al., 1998b). Alternatively, it
has been suggested that the predominant IgM response is associated with infection in
certain niches (e.g., the central nervous system in neuroborreliosis) (Fung et al., 1994;
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Mathiesen et al., 1998b). The data presented herein demonstrate that the C-terminus
can induce an IgG response following infection by needle inoculation in mice (Figure
17). Comparison of the reactivity of sera generated during infection with B31,
B31::ospC (wt), or B31::ospC (ΔC10) demonstrates that while C10 induces an IgG
response, it is not an immunodominant epitope. This is clearly demonstrated by the
similarity in IgG titers of mice infected with B31 versus B31::ospC (ΔC10) when
screened against r-OspC (wt) and r-OspC (ΔC10). The response to the C10 domain is
in agreement with previous epitope mapping studies, though the minor relative
contribution of the C10 domain was not evident in the non-quantitative maps (Earnhart
et al., 2005). Mapping studies have also demonstrated an early response to linear
epitopes in the loop 5 and alpha helix 5 regions (Earnhart et al., 2005). Based on the
current data, the sensitivity of an OspC-based diagnostic would likely be further
improved by inclusion of epitopes derived from regions outside of C10. Antibodies
generated against the OspC C10 epitope have been found to be bactericidal against
Borrelia in vivo (Lovrich et al., 2005; Lovrich et al., 2007). In contrast with earlier reports
of poor immunogenicity of this domain in mice (Lovrich et al., 2005), in the current study
there was clearly an induction of C10 specific IgG during infection. The induced
antibodies are specific to the C-terminus, as evidenced by the lack of any anti-C10
reactivity in mice infected with B31::ospC (ΔC10).
4.3 OspC LBD1 plays a crucial role in the ability of B. burgdorferi to establish
mammalian infection
While gene deletion analyses have advanced the understanding of when OspC
participates in the enzootic cycle, its biological function remains unknown (Earnhart et
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al., 2010; Fingerle et al., 2007; Gilmore and Piesman, 2000; Grimm et al., 2004; Pal et
al., 2004; Tilly et al., 2006; Tilly et al., 2007). In this study, the hypothesis that LBD1 is
a key determinant of OspC function in the mammalian environment was tested. Sitedirected mutations were introduced into the type A ospC gene of B. burgdorferi and the
mutated genes were transformed into an isogenic background. Residues K60, E61,
and E63, which are invariant or highly conserved (Earnhart and Marconi, 2007a) and
which possess side chains that extend into the solvent accessible pocket of LBD1, were
targeted for mutagenesis. Analysis of the resulting recombinant strains revealed that
the expression, export, and presentation of the modified proteins on the cell surface
were similar to the wild type strain. All strains maintained wild type growth rate and the
full complement of plasmids (with the exception of the non-essential lp21 in some
strains). Infectivity was assessed in mice through needle inoculation with cultivation
and seroconversion serving as the read out. The parental wildtype B31-5A4 strain
(untransformed), B31::ospC (wt), B31::ospC (E63Q), and the B31::ospC (K60Y) strains
were infectious while B31ΔospC, B31::ospC (E61Q/E63Q), and B31::ospC (E61Q)
strains were non-infectious. It is striking that a single amino acid substitution at position
61 proved sufficient to render cells non-infectious, presumably by inactivating the critical
functions associated with the OspC protein during the establishment of infection. For
those strains that retained infectivity, the possibility that the amino acid substitutions
introduced into LBD1 affect dissemination characteristics was assessed by determining
the number of spirochetes present at different anatomical sites by q-PCR. Higher
numbers of B31::ospC (E63Q) in the urinary bladder and lower numbers of B31::ospC
(K60Y) in the heart were observed (Earnhart et al., 2010). These results are consistent
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with the hypothesis that dissemination characteristics can be attributed, at least in part,
to the physiochemical properties of OspC (Alghaferi et al., 2005; Brisson and
Dykhuizen, 2004; Earnhart et al., 2005; Jones et al., 2006; Seinost et al., 1999;
Wormser et al., 2008).
There are several possible explanations for the inability of the B31::ospC (E61Q)
and B31::ospC (E61Q/E63Q) strains to establish infection. Since these strains are
isogenic derivatives of the parental strain, the most direct explanation is that the loss of
infectivity is a direct result of the modification of the OspC itself. The loss of infectivity
would imply that OspC has a specific function during early stage infection that cannot be
fulfilled by any other Borrelia protein. As discussed above, the biological properties of
these and control strains suggest that they are not compromised in any way. At the
molecular level, the amino acid substitutions could cause structural changes that ablate
function. However, this possibility is not supported by circular dichroism and
dimerization analyses that indicate that OspC structure and dimerization are largely
unaffected. A second possibility is a direct role for residue E61 as a ligand contact
point. Alternatively, E61 may indirectly influence the function of LBD1 through alteration
of its local surface charge. While this possibility cannot be ruled out, it is noteworthy
that the CD spectra for the E63Q and E61Q mutants which are associated with
infectivity and loss of infectivity, respectively, have nearly identical surface charge maps
(data not shown). In either case, it is clear that LBD1 and E61 are central in OspC‟s in
vivo function.
This data is the first to provide direct evidence that a specific domain of OspC is
required for in vivo function. Specifically, it has been demonstrated that residue E61 is
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required for infectivity and suggestive evidence has been provided that residues E63
and K60 influence dissemination. While these may not be the only functionally
important residues of OspC, the data firmly support the importance of LBD1 in OspC
function. The results presented here challenge recent hypotheses regarding the role of
OspC in Borrelia pathogenesis. Consistent with the phylogenetic, structural, and charge
properties of OspC, our lab favors the hypothesis that OspC binds a small ligand that
may be present in blood, extracellular fluid or possibly tissue that functions to facilitate
the adaptive changes required for survival during the early stages of infection. Once the
spirochetes adapt, OspC is no longer required and is down-regulated. Such a model is
consistent with the requirement of OspC for establishing infection in mice by tick or
needle inoculation routes but not by tissue transplantation (Tilly et al., 2006). In the
latter case, the spirochetes would already be “host-adapted” and would not require
OspC. With wild type and “loss of function” OspC mutant proteins in hand, it may be
possible to devise high-throughput screening assays designed to identify OspC ligands
that interact with LBD1 and thus unravel the function of OspC in Borrelia biology.
4.4 Alteration of surface charge on LBD2 of B. burgdorferi OspC results in a
failure to persist in the mouse model
The largest amount of intertype variability of OspC occurs in LBD2. This
variation results in great changes in the electrostatic potential of the protein in this area.
In order to investigate the role of surface charge of OspC LBD2 in B. burgdorferi
pathogenesis, two site-directed mutants were generated, B31::ospC (HNN) and
B31::ospC (NDE). Both of these mutants contained all the B31 plasmids, typical growth
rates, and express OspC normally. Upon infection in mice, it was found that the
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B31::ospC (HNN) mutant retained full infectivity and was able to disseminate to both ear
and bladder tissues. Conversely, the B31::ospC (NDE) mutant, while able to
disseminate normally, was completely cleared from mice by fourteen days postinoculation. This result indicated that the B31::ospC (NDE) mutant is unable to persist
in the mouse model.
There are several physicochemical differences between the B31::ospC (NDE)
mutant and the known B. burgdorferi OspC types, including differences in predicted
electrostatic surface charge and isoelectric point (pI). Electrostatic charge maps were
generated for both LBD2 mutants. The B31::ospC (HNN) mutant was found to have a
large dome of negative charge on LBD2 while the B31::ospC (NDE) mutant has very
little negative charge and an expansion of positive charge around LBD2. Charge maps
have been generated by our lab for several additional OspC types including OspC types
A, E, F, H, M, PKo and PBi. None of the OspC types that have been mapped have as
much positive charge on LBD2 as the B31::ospC (NDE) mutant. Additionally, the pI of
LBD2 was calculated for the OspC types commonly found in B. burgdorferi and for the
LBD2 mutants. While the pI of the B31::ospC (HNN) mutant (pI = 4.35) fell within the
range of the other OspC types (4.03 – 5.37), the pI of B31::ospC (NDE) LBD2 was
greater, being 6.28. These differences in surface charge and pI may account for the
differences in observed with the B31::ospC (NDE) mutant in vivo.
There have been other studies in which B. burgdorferi mutants were able to
cause infection but not persist in the animal model. For example, a previous study
expressed ospC in an ospC deletion strain on a nonessential plasmid. In this study
ospC was under the control of a constitutively active flaB promoter. When
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immunocompetent mice were inoculated with this strain, the only recoverable
spirochetes had lost this plasmid. Due to the fact that OspC is highly antigenic during
infection, a robust immune response is generated against this protein. It was suggested
that the anti-OspC immune response mounted by the host provides a selective pressure
against the spirochetes expressing OspC, clearing all spirochetes that did not lose the
plasmid (Tilly et al., 2006). This study was able to show that when OspC is not
downregulated in the correct timeframe, the humoral immune response is able to clear
the infection. Additionally, it has been shown that B. burgdorferi strains lacking the
plasmid lp28-1, which harbors the VlsE gene system, are cleared from
immunocompetent mice between seven and fourteen days post-inoculation (Embers et
al., 2008). It has also been demonstrated that spirochetes lacking lp28-1 showed
higher and sustained OspC production during the shortened infection in
immunocompetent mice, infection in SCID mice, and when cultured in dialysis
membrane chambers (DMCs). This study hypothesized that a repressor encoded on
lp28-1 is responsible for ospC downregulation and when this plasmid is missing,
continued OspC expression results in clearance by the humoral immune response
(Embers et al., 2008). Due to the fact that the surface charge of the B31::ospC (NDE)
mutant is changed significantly from that of other OspC types, the change in charge
could result in disrupted or altered interaction with this hypothesized repressor. If a
change in this interaction occurred, it would account for the lack of persistence of the
B31::ospC (NDE) mutant strain.
The research presented here on LBD2 suggests that the surface charge of the
variable portion of OspC plays an important role in the ability of B. burgdorferi to persist
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in mice during infection. The spirochetes are able to disseminate to multiple
organs/tissues in the body and induce an antibody response in the mice but the
infection is cleared between seven and fourteen days post-inoculation. This is the first
study to demonstrate the role of a specific portion of OspC in B. burgdorferi persistence.
In the future, studies to confirm antibody clearance of the B31::ospC (NDE) mutant by
the immune response will be performed in order to begin investigating the role of this
portion of OspC in ospC downregulation.
4.5 Allelic exchange replacement of ospC demonstrates the role of OspC phyletic
types in establishment of murine infection
Multiple OspC phyletic types have been identified from the Borrelia strains B.
burgdorferi, B. garinii, and B. afzelii. These different OspC types have been shown to
have type-specific differences in reservoir host specificity/association and in the
presence of human disseminated infection. In this study, multiple OspC types were
chosen to be inserted into the B31-5A4 genetic background using allelic exchange,
replacing the native OspC type A. For this study, OspC types were selected from a
variety of different Borrelia species. OspC types E, F, H, and M are found in the B.
burgdorferi strains DRI-83a, DRI-40g, LDS79, and Veery, respectively. OspC types PBi
and PKo were amplified from the European Lyme disease strains B. garinii strain PBi
and B. afzelii strain PKo and finally, the B. andersonii OspC types MOD-1, MOK-3a, and
MOS-1b were cloned from the strains of the same name. There were varying reasons
for the selection of these different OspC types including differences in tissue
dissemination, isolate origin, and host species specificity/association. To confirm the
infectivity status of the strains from which the OspC types were chosen, these strains
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were injected into mice and all were found to be infectious except for B. afzelii PKo and
all three B. andersonii strains. Once the selected OspC types were inserted into B315A4 in place of the native type A ospC gene, the resulting transgenic strains were used
to investigate the effect of OspC type alone on infectivity in the mouse. Most of the
transgenic strains were found to retain full infectivity in mice (B31::ospC (wt), B31::ospC
(E), B31::ospC (H), B31::ospC (M), B31::ospC (PBi), and B31::ospC (MOK-3a)) but four
strains showed altered infectivity. Two of the OspC type switch strains, B31::ospC (F)
and B31::ospC (MOS-1b), were cultivable from only one out of five mice inoculated with
these strains while another two transgenic strains, B31::ospC (PKo) and B31::ospC
(MOD-1), were unable to infect mice. This is the first study to show a relationship
between OspC type and infectivity in an animal model, regardless of the rest of the
genetic background of the infecting strain.
The wild type strains used in this analysis have varying host specificities. The
parental strain B. burgdorferi B31-5A4 is used extensively in vitro and is known to be
highly infectious in mice. This strain was originally isolated from a tick collected in New
York (Fraser et al., 1997). Several strains in this analysis were obtained from humans
with Lyme disease, including B. afzelii strain PKo, B. garinii strain PBi, and B.
burgdorferi strain LDS79. All these strains were found to infect mice except B. afzelii
PKo. This strain has previously been shown to be unable to cause murine infection
(Bockenstedt et al., 1997) but is able to infect gerbils (Preac-Mursic et al., 1992) and
hamsters (data not shown). Several of the wild type strains used in these analyses
were isolated from animals. The strains from which OspC types E and F were
amplified, DRI-83a and DRI-40g, were isolated from dogs experimentally infected with
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B. burgdorferi. OspC type M comes from the Veery strain which was isolated from a
bird (Anderson et al., 1986). Additionally, all of the B. andersonii strains used were
isolated from ticks obtained from rabbits (Lin et al., 2002). The differing locations of
origins of these isolates made them attractive candidates for an analysis into the role of
OspC in host specificity.
The cause for the lack of infectivity or reduced infectivity of the PKo, MOD-1, type
F, and MOS-1b transgenic strains could be attributed to multiple possibilities. The
B31::ospC (type PKo) and B31::ospC (type MOD-1) support the hypothesis that the
OspC protein mediates infectivity in different hosts. The B31::ospC (type PKo) strain
did not grow out of any organs nor did the mice inoculated with this strain show any
seroconversion. As the only difference between this strain and the parental B31-5A4 is
the presence of OspC type PKo instead of OspC type A, it is possible that it is the
presence of OspC type PKo that renders this previously infectious strain non-infectious
in mice. The B31::ospC (MOD-1) strain is also noncultivable, yet the mice inoculated
with this strain did seroconvert at a very low level. The B31::ospC (MOS-1b) strain was
only able to be cultivated out of one mouse and showed a low level of seroconversion.
With the wild type B. andersonii MOD-1 and MOS-1b strains both being noninfectious,
these results indicate that perhaps these two strains were able to set up but not
maintain a long term infection in mice. These three transgenic strains support the
hypothesis that OspC plays a role in the ability of B. burgdorferi to infect mice.
The infection data from two transgenic and wild type strains contradict the data
presented above. First, the wild type strain for OspC type F was found to be fully
infectious in mice while the transgenic strain, B31::ospC (type F), showed reduced
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infectivity. Of the five mice inoculated with this strain, only one mouse showed
spirochete grow out and several others produced low level seroconversion. This could
be due to altered dissemination. Only ear and bladder tissues were used for infectivity
analysis. It is possible that the B31::ospC (type F) strain has altered dissemination and
was not present in detectable numbers in the tissues that we collected. Repeating this
infection and sampling more tissues might help to clarify this result. The data obtained
from the wild type and transgenic strains harboring OspC type MOK-3a produced
results that are actually the opposite of the hypothesis. The wild type B. andersonii
strain was noninfectious in mice but the transgenic strain was both cultivable and
induced a robust immune response. This result could be due to problems with the wild
type strain. This strain was isolated from a nymphal tick collected off of a rabbit. The
full plasmid repertoire of B. andersonii is not known so it is possible that the wild type B.
andersonii MOK-3a strain is missing plasmids necessary for infection. If this is the case
and lack of infectivity of the wild type strain is due to a factor other than the OspC type,
full infectivity of the transgenic strain would be expected. Further analysis of these wild
type and transgenic strains is warranted to clarify these results.
In summary, B31-5A4 mutants expressing different OspC types have been used
to show a relationship between OspC type and infectivity in mice. These analyses have
shown that OspC type alone is enough to render a previously infectious strain noninfectious. While further research is needed to fully understand this relationship, it is
clear that OspC type does play a role in the ability of B. burgdorferi to infect certain
hosts.
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4.6 Investigation of the domain of OspC that influences host specificity of the
Lyme Borrelia
OspC types A and PKo have been shown to have differing host specificities. As
discussed above, the B. burgdorferi B31-5A4 strain that expresses OspC type A is
highly infectious in mice while the B. afzelii strain PKo that expresses OspC type PKo is
not. As described in the above section, an allelic exchange mutant of B31-5A4
expressing OspC type PKo instead of type A completely lost the ability to cause
infection in mice. In order to further investigate this finding, B31-5A4 mutants were
created that express OspC hybrids of types A and PKo. Infectivity analysis showed that
in addition to the B31::ospC (type PKo) strain only one OspC hybrid-expressing strain,
B31::ospC (hybrid Paa), lost the ability to maintain an infection in mice.
There are a variety of reasons that this particular transgenic strain was
uncultivable from mice. The strains B31::ospC (type PKo) and B31::ospC (hybrid Paa)
have both similarities and differences. Both strains contain the exact same genetic
background and only have one plasmid difference. B31::ospC (type PKo) is missing
plasmid lp5, which has been shown to have no effect on in vitro cultivation. Both of
these strains were shown to export and present OspC at the same levels as all other
strains tested while also growing in vitro at the same rate. Lastly, both strains, along
with the fully infectious hybrids B31::ospC (hybrid Pap) and B31::ospC (hybrid Ppa),
contain the core of OspC type PKo, which includes LBD1. The major difference
between these strains exists on the LBD2 portion of the protein. The B31::ospC (hybrid
Paa) strain expresses an OspC protein with the full type A LBD2. B31-5A4, when
expressing OspC type A, is highly infectious in mice. Therefore, all portions of the
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hybrid Paa OspC protein can be found in strains that are infectious in the mouse. This
data suggests that there is not one clear potion of OspC that is involved in infectivity in a
particular host.
The mice inoculated with the B31::ospC (hybrid Paa) strain generated a low but
detectable immune response (Figure 28). This suggests that, like many of the
previously described mutant strains, the B31::ospC (hybrid Paa) mutant was able to
briefly establish an infection but was then cleared. It is thought that OspC plays multiple
roles in the pathogenesis of B. burgdorferi and mutants such as the B31::ospC (hybrid
Paa) strain indicate that perhaps not all OspC proteins are able to carry out the different
functions of this protein. This could be the cause for very little observed recombination
of OspC in nature. Perhaps recombination events occur more regularly than previously
thought but the new OspC types are not functional. In summary, based on these
results it appears that no one portion of OspC mediates the ability of B. burgdorferi to
infect different animals.
4.7 Summary
The data presented in this dissertation reflects the great body of knowledge
about OspC that has been generated by our lab. OspC is one of the few known
virulence factors of B. burgdorferi and the study of the structure/function relationships of
this protein is complicated by the lack of an identified functional ligand and/or a defined
mechanism of action. Our lab has developed a novel approach to study this protein by
creating allelic exchange mutants that express any OspC type or mutant from the native
location of ospC in the B. burgdorferi genome. Most studies focusing on OspC utilize
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deletion strains that express ospC mutations from a plasmid (Pal et al., 2004; Tilly et al.,
2006; Tilly et al., 2007; Yang et al., 2005). The method used in our lab allows us to
study OspC that is expressed in the same way as wild type and without differences in
plasmid copy number. Also, creating allelic exchange mutants has allowed for the
targeted study of different portions of OspC and how these portions play a role in OspC
function without having a defined ligand. Using this allelic exchange method and
generating many different mutations to the conserved and variable portions of OspC
has helped our lab to create a comprehensive map of the structure function
relationships of OspC. These mutants provide an ideal tool for deciphering the ligand
and/or function of OspC.
The calculated size of the solvent accessible pocket of LBD1 suggests its
potential ligands would be relatively small (Eicken et al., 2001; Kumaran et al., 2001b).
It was postulated in an earlier study that the region of OspC, designated by our lab as
LBD1, may be an aspartate binding domain (Eicken et al., 2001). The Salmonella
typhimurium aspartate receptor, which is involved in chemotaxis and signaling (Yeh et
al., 1996), possesses a four alpha helical bundle similar to that present in OspC.
However, other than structural similarity there is no discernable sequence homology
between these proteins. While it seems unlikely that OspC binds aspartate, the general
hypothesis that LBD1 is involved in the binding of small ligands is supported by its
structural properties, the results presented herein. While the identity of the ligands that
interact with LBD1 remain unknown, there is now strong and compelling evidence that
LBD1 is a key functional determinant of OspC that plays an essential role in the
establishment of infection in mammals.
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It is important to note that OspC has been reported to bind at least two other
ligands, the Salp15 protein of Ixodes ticks (Das et al., 2001; Hovius et al., 2007) and the
mammalian-derived protein plasminogen (Lagal et al., 2006). The domains and
residues of OspC that are involved in these interactions have not been identified. In this
dissertation, the OspC interaction with Salp-15 was not specifically assessed.
Plasminogen binding assays were conducted with all mutant strains described in this
dissertation (Figure 16 and data not shown). None of the mutants displayed attenuated
plasminogen binding, therefore it does not appear that plasminogen is the critical ligand
for OspC. Interestingly, the E61Q/E63Q protein, a mutant strain that was shown to be
noninfectious, bound plasminogen at a higher level than wild type protein. The extent to
which the OspC-plasminogen interaction contributes to pathogenesis remains to be
directly assessed and such analyses are complicated by the fact that Borrelia produce
several plasminogen binding proteins including OspE and CspZ (factor H binding
proteins) (Brissette et al., 2009; Hovis et al., 2006).
Several opposing hypotheses have been offered regarding OspC function
(Radolf and Caimano, 2008). It has been postulated that OspC does not have a
specific or unique function and instead, by simple virtue of its abundance, serves to
maintain membrane integrity (Xu et al., 2008). It was reported that the introduction of
random lipoprotein genes (OspE, OspA, VlsE and DbpA) on an autonomously
replicating plasmid restored infectivity to an ospC knock out strain in SCID mice (but
less so in immunocompetent mice). From this it was concluded that structurally
unrelated proteins are functionally equivalent (i.e., the “surrogate hypothesis”). If OspC
can be replaced by randomly selected, unrelated Borrelia lipoproteins, it is not clear why
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OspC variants with single amino acid substitutions that are unaltered in structure and
expressed at wild type levels, cannot complement the putative membrane integrity
maintenance function of OspC. In addition, if OspC could be replaced by other
lipoproteins, it could be argued that ospC-deficient strains would have emerged in
nature since there would be no selective advantage in maintaining such a gene.
Analyses of hundreds of Lyme disease isolates have showed that OspC is universal in
all Lyme Borrelia species and homologs are carried by all relapsing fever spirochete
species and isolates [(Marconi et al., 1993b; Margolis et al., 1994). These facts,
coupled with ospC phylogenetic analyses which indicate selective constraints on OspC
sequence variation within specific domains, including LBD1, C10, and C130 (Attie et al.,
2007; Baranton et al., 2001; Earnhart and Marconi, 2007a; Lagal et al., 2002; Lin et al.,
2002; Qiu et al., 2008; Theisen et al., 1993), strongly argue against the “surrogate
hypothesis”.
In this dissertation, we have presented the first studies to (a) demonstrate the
presence of OspC oligomers in vitro and in vivo while also identifying the residue that
mediates oligomer formation, (b) identify a specific domain and a single amino acid
critical to OspC function, (c) demonstrate that changes in OspC surface charge can
alter persistence, and (d) abolish infectivity in a certain host by changing only the OspC
type expressed by the inoculating strain. We have also shown that the C10 portion of
OspC does not appear to interact with plasminogen or have a role in infectivity. In
conclusion, it is clear that OspC plays a vital role in the ability of B. burgdorferi to cause
infection and that the many functional roles of OspC are mediated by domains/residues
in both the conserved and variable portions of this protein. The research presented in
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this dissertation has added significantly to the body of knowledge of the role of OspC in
B. burgdorferi pathogenesis.
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